Phreesia (PHR) 10-K 23 Apr 20 2020 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Jan. 31, 2020	Apr. 21, 2020	Jul. 31, 2019
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 31, 2020
Document Transition Report	false
Entity File Number	001-38977
Entity Registrant Name	PHREESIA, INC.
Entity Central Index Key	0001412408
Current Fiscal Year End Date	--01-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2275479
Entity Address, Address Line One	432 Park Avenue South
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	888
Local Phone Number	654-7473
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	PHR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 511,181,113
Entity Common Stock, Shares Outstanding		37,516,058
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Definitive Proxy Statement relating to its 2020 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.

Balance sheets

Balance sheets - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Current:
Cash and cash equivalents	$ 90,315	$ 1,543
Settlement assets	12,368	10,217
Accounts receivable, net of allowance for doubtful accounts of $943 and $517	21,978	16,073
Deferred contract acquisition costs	1,720	1,673
Prepaid expenses and other current assets	5,157	3,811
Total current assets	131,538	33,317
Property and equipment, net of accumulated depreciation and amortization of $35,551 and $27,862	14,487	14,211
Capitalized Internal-use software, net of accumulated amortization of $19,554 and $14,621	8,735	7,816
Deferred contract acquisition costs	1,594	1,521
Intangibles assets, net of accumulated amortization of $271 and $33	1,199	1,437
Long-term deferred tax assets	775	0
Goodwill	250	250
Other assets	180	710
Total assets	158,758	59,262
Current:
Settlement obligations	12,368	10,217
Current portion of long-term debt	0	97
Current portion of capital leases	2,324	1,869
Accounts payable	6,017	3,750
Accrued expenses	9,243	5,507
Deferred revenue	5,401	6,488
Total current liabilities	35,353	27,929
Long-term debt, net of current portion	19,444	27,918
Capital leases, net of current portion	2,096	2,401
Warrant liability	0	5,498
Total liabilities	56,893	63,746
Commitments and contingencies (Note 12)
Redeemable preferred stock:
Redeemable preferred stock value	0	206,490
Stockholders’ Equity (Deficit):
Common stock, $0.01 par value—500,000,000 and 80,000,000 shares authorized as of January 31, 2020 and January 31, 2019, respectively; 36,610,763 and 1,994,721 shares issued and outstanding at January 31, 2020 and 2019, respectively;	366	20
Additional paid-in capital	386,383	0
Accumulated deficit	(284,485)	(210,994)
Treasury stock	(399)	0
Total stockholders’ equity (deficit)	101,865	(210,974)
Total Liabilities, Redeemable Preferred Stock and Stockholders’ Equity (Deficit)	158,758	59,262
Senior redeemable convertible preferred stock (Senior A)
Redeemable preferred stock:
Redeemable preferred stock value	0	79,311
Senior redeemable convertible preferred stock (Senior B)
Redeemable preferred stock:
Redeemable preferred stock value	0	51,872
Junior convertible preferred stock
Redeemable preferred stock:
Redeemable preferred stock value	0	32,746
Redeemable preferred stock
Redeemable preferred stock:
Redeemable preferred stock value	$ 0	$ 42,561

Balance sheets (Parenthetical)

Balance sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Allowance for doubtful accounts	$ 943	$ 517
Accumulated depreciation and amortization, property and equipment	35,551	27,862
Accumulated amortization, capitalized internal-use software	19,554	14,621
Accumulated amortization, intangible assets	$ 271	$ 33
Temporary equity, shares outstanding (in shares)		98,178,078
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	80,000,000
Common stock, shares issued (in shares)	36,610,763	1,994,721
Common stock, shares outstanding (in shares)	36,610,763	1,994,721
Senior redeemable convertible preferred stock (Senior A)
Temporary equity, par value (in usd per share)		$ 0.01
Temporary equity, shares authorized (in shares)		14,500,000
Temporary equity, shares issued (in shares)		13,674,365
Temporary equity, shares outstanding (in shares)		13,674,365
Senior redeemable convertible preferred stock (Senior B)
Temporary equity, par value (in usd per share)		$ 0.01
Temporary equity, shares authorized (in shares)		10,820,169
Temporary equity, shares issued (in shares)		9,197,142
Temporary equity, shares outstanding (in shares)	0	9,197,142
Junior convertible preferred stock
Temporary equity, par value (in usd per share)		$ 0.01
Temporary equity, shares authorized (in shares)		34,000,000
Temporary equity, shares issued (in shares)		32,746,041
Temporary equity, shares outstanding (in shares)	0	32,746,041
Redeemable preferred stock
Temporary equity, par value (in usd per share)		$ 0.01
Temporary equity, shares authorized (in shares)		44,000,000
Temporary equity, shares issued (in shares)		42,560,530
Temporary equity, shares outstanding (in shares)	0	42,560,530

Statements of operations

Statements of operations - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Revenue:
Revenues	$ 124,784	$ 99,889	$ 79,834
Expenses:
Cost of revenue (excluding depreciation and amortization)	16,831	15,105	12,562
Payment processing expense	27,889	21,892	17,209
Sales and marketing	32,357	26,367	24,761
Research and development	18,623	14,349	11,377
General and administrative	30,458	20,076	18,838
Depreciation	8,753	7,552	6,832
Amortization	5,171	4,042	2,808
Total expenses	140,082	109,382	94,387
Operating loss	(15,298)	(9,494)	(14,553)
Other income (expense)	(1,023)	(7)	602
Change in fair value of warrant liability	(3,307)	(2,058)	(598)
Interest income (expense)	(2,445)	(3,504)	(3,642)
Total other income (expense)	(6,775)	(5,568)	(3,639)
Loss before benefit from (provision for) income taxes	(22,073)	(15,062)	(18,192)
Benefit from (provision for) income taxes	1,780	0	0
Net loss	(20,293)	(15,062)	(18,192)
Preferred stock dividends paid	(14,955)	0	0
Accretion of redeemable preferred stock	(56,175)	(30,199)	(19,981)
Net loss attributable to common stockholders	$ (91,423)	$ (45,261)	$ (38,173)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share)	$ (4.50)	$ (24.53)	$ (24.81)
Weighted-average common shares outstanding, basic and diluted (in shares)	20,301,189	1,844,929	1,538,600
Subscription and related services
Revenue:
Revenues	$ 56,357	$ 43,928	$ 32,430
Payment processing fees
Revenue:
Revenues from contract with customer	46,500	36,881	28,671
Life sciences
Revenue:
Revenues from contract with customer	$ 21,927	$ 19,080	$ 18,733

Statements of redeemable prefer

Statements of redeemable preferred stock and stockholders' equity (deficit) - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated deficit	Treasury stock	Senior redeemable convertible preferred stock (Senior A)	Senior redeemable convertible preferred stock (Senior B)	Junior convertible preferred stock	Redeemable preferred stock
Beginning balance, redeemable preferred stock (in shares) at Jan. 31, 2017						13,674,365	0	32,718,098	42,560,530
Beginning balance, redeemable preferred stock at Jan. 31, 2017	$ 123,823					$ 48,544	$ 0	$ 32,718	$ 42,561
Redeemable preferred stock
Issuance of redeemable convertible preferred stock (in shares)							9,197,142
Issuance of redeemable convertible preferred stock	32,459						$ 32,459
Net exercise of warrants (in shares)								27,943
Net exercise of warrants	28							$ 28
Accretion of redeemable preferred stock	19,981					$ 8,478	$ 11,503
Ending balance, redeemable preferred stock (in shares) at Jan. 31, 2018						13,674,365	9,197,142	32,746,041	42,560,530
Ending balance, redeemable preferred stock at Jan. 31, 2018	176,291					$ 57,022	$ 43,962	$ 32,746	$ 42,561
Beginning balance, stockholders' equity (in shares) at Jan. 31, 2017		1,494,731
Beginning balance, stockholders' equity (deficit) at Jan. 31, 2017	(130,462)	$ 15	$ 0	$ (130,477)
Stockholders’ equity (deficit)
Net loss	(18,192)			(18,192)
Stock-based compensation expense	805		805
Exercise of stock options (in shares)		143,600
Exercise of stock options and release of restricted stock units	147	$ 1	146
Accretion of redeemable preferred stock	(19,981)		(951)	(19,031)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2018		1,638,331
Ending balance, stockholders' equity (deficit) at Jan. 31, 2018	(167,683)	$ 16	0	(167,700)
Redeemable preferred stock
Accretion of redeemable preferred stock	$ 30,199					$ 22,289	$ 7,910
Ending balance, redeemable preferred stock (in shares) at Jan. 31, 2019	98,178,078					13,674,365	9,197,142	32,746,041	42,560,530
Ending balance, redeemable preferred stock at Jan. 31, 2019	$ 206,490					$ 79,311	$ 51,872	$ 32,746	$ 42,561
Stockholders’ equity (deficit)
Net loss	(15,062)			(15,062)
Stock-based compensation expense	$ 1,447		1,447
Exercise of stock options (in shares)	316,063	316,063
Exercise of stock options and release of restricted stock units	$ 361	$ 3	358
Accretion of redeemable preferred stock	(30,199)		(1,967)	(28,232)
Issuance of common stock in connection with acquisition (in shares)		40,327
Issuance of common stock in connection with acquisition	163	$ 1	162
Ending balance, stockholders' equity (in shares) at Jan. 31, 2019		1,994,721
Ending balance, stockholders' equity (deficit) at Jan. 31, 2019	(210,974)	$ 20	0	(210,994)
Redeemable preferred stock
Accretion of redeemable preferred stock	56,175					$ 32,706	$ 23,469
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)						(13,674,365)	(9,197,142)	(32,746,041)	(42,560,530)
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	(262,665)					$ (112,018)	$ (75,341)	$ (32,746)	$ (42,561)
Ending balance, redeemable preferred stock (in shares) at Jan. 31, 2020							0	0	0
Ending balance, redeemable preferred stock at Jan. 31, 2020	0					$ 0	$ 0	$ 0	$ 0
Stockholders’ equity (deficit)
Net loss	(20,293)			(20,293)
Stock-based compensation expense	$ 6,177		6,177
Exercise of stock options (in shares)	691,371	734,382
Exercise of stock options and release of restricted stock units	$ 1,809	$ 7	1,802
Issuance of common stock warrants	833		833
Accretion of redeemable preferred stock	(56,175)		(2,977)	(53,198)
Payment of preferred stock dividends	(14,955)		(14,955)
Issuance of common stock in initial public offering, net of issuance costs (in shares)		7,812,500
Issuance of common stock in initial public offering, net of issuance costs	124,370	$ 78	124,292
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock	$ 262,665	$ 253	262,412
Cashless exercise of common stock warrants (in shares)	168,862	168,862
Cashless exercise of common stock warrants	$ 2	$ 2
Conversion and exercise of preferred stock warrants into common stock (in shares)		588,763
Conversion and exercise of preferred stock warrants into common stock	8,805	$ 6	8,799
Treasury stock from option exercises	399				399
Ending balance, stockholders' equity (in shares) at Jan. 31, 2020		36,610,763
Ending balance, stockholders' equity (deficit) at Jan. 31, 2020	101,865	$ 366	$ 386,383	$ (284,485)	$ (399)
Stockholders’ equity (deficit)
Issuance costs	$ 6,412

Statements of redeemable pref_2

Statements of redeemable preferred stock and stockholders' equity (deficit) (Parenthetical) - USD ($) $ in Thousands	Nov. 29, 2017	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Payment of offering costs		$ 6,217	$ 195	$ 0
Issuance costs		$ 6,412
Senior redeemable convertible preferred stock (Senior B)
Payment of offering costs	$ 1,541			$ 1,541

Statements of cash flows

Statements of cash flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (20,293)	$ (15,062)	$ (18,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,924	11,594	9,640
Stock-based compensation expense	6,177	1,447	805
Change in fair value of warrants liability	3,307	2,058	598
Amortization of debt discount	445	798	904
Loss on extinguishment of debt	1,073	0	0
Cost of Phreesia hardware purchased by customers	741	585	0
Deferred contract acquisition cost amortization	1,977	1,640	1,389
Deferred tax asset	(775)	0	0
Changes in operating assets and liabilities
Accounts receivable	(5,905)	(3,765)	(3,382)
Prepaid expenses and other assets	(312)	(576)	(319)
Deferred contract acquisition costs	(2,097)	(2,500)	(1,773)
Accounts payable	(30)	2,367	(2,057)
Accrued expenses	3,681	(2,317)	1,968
Deferred revenue	(1,087)	1,601	(723)
Net cash provided by (used in) operating activities	826	(2,130)	(11,142)
Cash flows used in investing activities:
Acquisition	0	(1,190)	0
Capitalized internal-use software	(5,305)	(5,109)	(5,375)
Purchases of property and equipment	(7,015)	(4,724)	(6,590)
Net cash used in investing activities	(12,320)	(11,023)	(11,965)
Cash flows from financing activities:
Proceeds from IPO	130,781	0	0
Proceeds from revolving line of credit	9,876	14,800	12,400
Payments of revolving line of credit	(17,676)	(7,000)	(20,400)
Proceeds from term loan	20,000	0	0
Proceeds from loan payable	0	0	10,000
Repayment of term loan	(1,042)	(1,167)	(1,167)
Repayment of loan payable	(20,000)	0	0
Payment of preferred stock dividends	(14,955)	0	0
Payments of capital leases	(1,898)	(2,470)	(1,929)
Debt extinguishment costs	(300)	0	0
Debt issuance costs	(112)	(136)	(224)
Proceeds from issuance of preferred stock, net	0	0	32,459
Proceeds from issuance of common stock upon exercise of stock options	1,809	361	147
Payment of offering costs	(6,217)	(195)	0
Net cash provided by financing activities	100,266	4,193	31,286
Net increase (decrease) in cash and cash equivalents	88,772	(8,960)	8,179
Cash and cash equivalents—beginning of year	1,543	10,503	2,323
Cash and cash equivalents—end of year	90,315	1,543	10,503
Supplemental information:
Property and equipment acquisitions through capital leases	2,047	4,425	781
Deferred debt issuance costs included in accrued expenses	0	0	100
Deferred issuance costs included in accounts payable and accrued expenses	0	344	0
Purchase of property and equipment and capitalized software included in accounts payable	1,253	0	0
Shares issued in connection with acquisition	0	162	0
Issuance of warrants related to debt	833	0	0
Net exercise of preferred stock warrant	0	0	28
Cash paid for:
Interest	$ 2,310	$ 2,799	$ 2,799

Background and liquidity

Background and liquidity	12 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	Background and liquidity (a) Background Phreesia, Inc. (the Company) is a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the Phreesia Platform), the Company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and an integrated payments solution for secure processing of patient payments. The Company’s Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. The Company was formed in May 2005, and has its corporate headquarters in New York, and operations offices in Raleigh, North Carolina and Ottawa, Canada. (b) Recapitalization The Company effected a 0.4551-for-1 reverse split of its common stock on July 3, 2019. The reverse split combined each approximately 2.1973 shares of the Company’s issued and outstanding common stock into one share of common stock and correspondingly adjusted the conversion price of its convertible preferred stock. No fractional shares were issued in connection with the reverse split. Any fractional share resulting from the reverse split was rounded down to the nearest whole share, and in lieu of any fractional shares, the Company will pay in cash to the holders of such fractional shares an amount equal to the fair market value, as determined by the board of directors, of such fractional shares. All share, per share and related information presented in the financial statements and accompanying notes have been retroactively adjusted, where applicable, to reflect the reverse stock split. (c) Initial public offering On July 22, 2019, the Company closed its initial public offering (IPO), in which the Company issued and sold 7,812,500 shares of common stock at a public offering price of $18.00 per share, resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions of $9,844 but before deducting deferred offering costs of $6,412. In addition to the shares of common stock sold by the Company upon the IPO, certain selling stockholders sold an aggregate 2,868,923 shares of common stock as part of the IPO. Upon closing of the IPO, the Company's outstanding shares of Senior A redeemable convertible preferred stock (Senior A Preferred), Senior B redeemable convertible preferred stock (Senior B Preferred, and together with the Senior A Preferred, the Senior Preferred), and the Junior convertible preferred stock (the Junior Preferred, and together with the Senior Preferred, the Convertible Preferred) automatically converted into shares of common stock and all outstanding shares of the Company's redeemable preferred stock (Redeemable Preferred) were automatically extinguished and cancelled at the closing of the IPO. In addition, the Company's warrants to purchase shares of Senior Preferred were converted into warrants to purchase shares of the Company's common stock upon the closing of the IPO. Additionally, 588,763 shares of common stock were issued upon the cashless exercise of common stock warrants (See Note 10). Also, in connection with the IPO, the Company paid $14,955 in dividends to the Senior Preferred stockholders. On December 17, 2019, the Company closed its follow-on offering of 7,762,500 shares of common stock sold by certain selling stockholders. The Company did not receive any proceeds from the follow-on offering but did incur $1,047 in transaction costs, recorded through the general and administrative line on the statement of operations. d) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, preferred stock, and debt to fund its operations as well as sales in the normal course of business. Management believes that losses and negative cash flows will continue for at least the next year. Management believes that the Company’s cash and cash equivalents at January 31, 2020 along with cash generated in the normal course of business, and available borrowing capacity under its February 2019 Credit

Basis of presentation

Basis of presentation	12 Months Ended
	Jan. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation (a) Basis of presentation The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada. (b) Fiscal year The Company’s fiscal year ends on January 31, 2020. References to fiscal 2020, 2019, and 2018 refer to the fiscal year ended January 31, 2020, 2019, and 2018, respectively. (c) Reclassifications A reclassification was made from amounts included in accounts payable to accrued liabilities and from amounts included in accounts receivable to prepaid and other current assets on the balance sheet and statement of cash flows as of January 31, 2019 to conform and be comparable to the presentation on the balance sheet and statement of cash flows as of January 31, 2020. A reclassification was also made to reflect the deferred contract acquisition costs as an adjustment to net loss on the statement of cash flows as of January 31, 2019 and January 31, 2018 to conform and be comparable to the presentation on the statement of cash flows as of January 31, 2020. In the prior periods, the deferred contract acquisition costs were netted against the change in the assets. The reclassifications had no effect on net earnings or cash flows as previously reported.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies (a) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of stock warrants, the fair value of its business acquisitions, and the realization of deferred tax assets. (b) Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information about the adoption of ASC 606, Revenue from Contracts with Customers, as well as for additional details about the Company's products and service lines. (c) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Platform such as hosting fees, certain fees paid to various third party partners for the use of their technology, and personnel expenses for implementation and technical support. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation. (d) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks and that are ultimately paid to the card-issuing financial institution, assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways. (e) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $251, $134, and $17 for the fiscal years ended 2020, 2019, and 2018, respectively. (f) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period. (g) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. (h) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Stations (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. (i) Amortization Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets. (j) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. (k) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two (l) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. (m) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time accounts are past due, a customer’s current ability to pay its obligations to the Company, and the condition of the industry as a whole. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2020 and 2019, the Company has reserved $943 and $517 for the allowance for doubtful accounts. Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5). (n) Property and equipment Property and equipment, including PhreesiaPads, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three seven Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations. (o) Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC Topic 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period. (p) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the statement of operations. (q) Goodwill and intangible assets Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, it is necessary to perform the two-step goodwill impairment test. The two-step goodwill impairment test begins with a comparison of the estimated fair value of the reporting unit to the carrying value of the reporting unit. The first step, commonly referred to as a “step-one impairment test,” is a screen for potential impairment while the second step measures the amount of impairment if there is an indication from the first step that one exists. All other intangible assets associated with purchased intangibles, consisting of customer relationships and acquired technology are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. (r) Long-lived assets Long-lived assets, such as property and equipment and intangible assets, including capitalized internal-use software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented. (s) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, disclosure, and transition. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision (benefit) from income taxes. (t) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the financial statements. (u) Redeemable preferred stock All of the Company’s redeemable preferred stock was classified outside of stockholders’ deficit because the shares contain certain redemption features that are not solely within the control of the Company. At the time of issuance, the redeemable preferred stock was recorded at its issuance price, less issuance costs. The carrying values of the Senior Preferred were accreted to their redemption values at each reporting period, which was equal to the greater of (i) the original issuance price plus unpaid accrued dividends or (ii) the fair value of the Senior Preferred. The Junior Preferred and Redeemable Preferred were accreted to their redemption amount, which is $1.00 per share. The Company records changes in the redemption value of redeemable preferred stock immediately as they occur as if the end of the reporting period was the redemption date for the instrument. As of the year ended January 31, 2020, all redeemable preferred stock has been converted or cancelled in connection with the IPO on July 22, 2019. (v) Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs), and performance-based RSUs. The compensation for the stock-based awards is recognized in accordance with ASC 718, Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the estimated fair value of the underlying common stock, exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, the most critical of which is the estimated fair value of the Company’s common stock. The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. (w) Warrant liability Warrants to purchase shares of the Company’s redeemable preferred stock were classified as warrant liability on the fiscal 2019 accompanying balance sheet and recorded at fair value. This warrant liability was subject to re-measurement at each balance sheet date and the Company recognized any change in fair value in its statements of operations as a change in fair value of the warrant liability. The Company adjusted the carrying value of the warrants for changes in the estimated fair value in all periods leading up to the IPO, at which time such warrants converted into warrants to purchase shares of common stock. In connection with the IPO, the liabilities were reclassified to additional paid-in capital, a component of stockholders’ deficit. (x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under generally accepted accounting principles. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. (y) Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of Cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for fiscal 2020 and fiscal 2019. As of January 31, 2020, one customer accounted for 15% of accounts receivable. As of January 31, 2019, the Company did not have any individual customers that represented more than 10% of accounts receivable. (z) Deferred offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the statement of operations. Refer to Note 4(e) for further detail on deferred offering costs for the periods presented. (aa) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other income (expense). (bb) New accounting pronouncements JOBS Act accounting election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company has elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently adopted accounting pronouncements In March 2016, the FASB issued ASU 2016-9, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , with guidance regarding the simplification of accounting for share-based payment award transactions. The update changes the accounting for such areas as the accounting and cash flow classification for excess tax benefits and deficiencies; forfeitures; and tax withholding requirements and cash flow classification. This guidance was effective for public companies for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company adopted the new guidance effective February 1, 2017, and it did not have a material effect on its financial statements. In May 2017, the FASB issued ASU 2017-9, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting , which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance was effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU are applied prospectively to an award modified on or after the adoption date. The Company adopted the new guidance effective February 1, 2018, and it did not have a material effect on its financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments , with guidance intended to reduce the diversity in practice regarding how certain cash receipts and cash payments are presented and classified within the statement of cash flows. The update addresses eight specific cash flow issues including: debt prepayment or debt extinguishment costs; the settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies or bank-owned life insurance policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. This guidance was effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted the new guidance effective February 1, 2018, and it did not have a material effect on its financial statements. In June 2018, the FASB issued ASU 2018-7, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which largely aligns the accounting for share-based payment awards issued to nonemployees with the accounting for share-based payment awards issued to employees. Under previous GAAP, the accounting for nonemployee share-based payments differed from that applied to employee awards, particularly with regard to the measurement date and the impact of performance conditions. Under the new guidance, (i) equity-classified share-based payment awards issued to nonemployees will be measured at the grant date, instead of the previous requirement to re-measure the awards through the performance completion date, (ii) for performance conditions, compensation cost associated with the award will be recognized when the achievement of the performance condition is probable, rather than upon achievement of the performance condition, and (iii) the current requirement to reassess the classification (equity or liability) for nonemployee awards upon vesting will be eliminated, except for awards in the form of convertible instruments. This new guidance is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year and early adoption is permitted. The Company adopted ASU 2018-7 as of February 1, 2018 and the impact was not material. Recent accounting pronouncement not yet adopted In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). ASU 2018-13 updates the disclosure requirements for fair value measurements and is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of this standard on the Company’s financial statements. On February 1, 2020, the Company adopted FASB ASU No. 2016-02, Leases (Topic 842) which requires lessees to record most leases on their balance sheets but to recognize the expenses in their statement of operations in a manner similar to the prior standard. Topic 842 states that a lessee recognizes a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The Company adopted the new lease guidance using a modified retrospective transition method applied to those leases which were not completed as of February 1, 2020. As a result, the Company was not required to adjust its comparative period financial information for effects of the standard or make the new required lease disclosures for the periods before the date of adoption. The Company elected the ‘package of practical expedients,’ which permits the Company not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all of its leases. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, including existing short-term leases as of the transition date. The Company also elected the practical expedient to not separate lease and non-lease components for all leases. Upon adoption of Topic 842 we expect to recognize operating lease right-of-use assets and operating lease liabilities related to our office leases of approximately $2.8 million and $3.0 million, respectively. The Company’s accounting for lessee finance and all lessor leases remains substantially unchanged from legacy guidance. The standard is not expected to have a significant impact on our statements of operations or statements of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The update requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument. We adopted the new guidance effective February 1, 2020, and it did not have a material effect on our financial statements. (cc) Risks and uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws, government regulations, and other risks associated with the markets in which we operate including reliance on third party vendors, partners, and service providers. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of our business and our customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of our operations, adversely impacting the Company’s operating results and our ability to meet our obligations and commitments.

Composition of certain financia

Composition of certain financial statement captions	12 Months Ended
	Jan. 31, 2020
Composition of Certain Financial Statement Captions [Abstract]
Composition of certain financial statement captions	Composition of certain financial statement captions (a) Accrued expenses Accrued expenses at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Payment processing fees liability $ 2,738 $ 2,267 Commission and bonus 3,100 320 Payroll 1,360 267 Accrued payment related to acquisition of Vital Score — 350 Vacation 573 417 Other 1,472 1,886 Total $ 9,243 $ 5,507 (b) Property and equipment Property and equipment at January 31, 2020 and 2019 are as follows: Useful life January 31, 2020 2019 PhreesiaPads and Arrivals Stations 3 $ 26,389 $ 22,747 Computer equipment 3 18,394 14,338 Computer software 3 2,297 2,166 Hardware development 3 1,024 1,024 Furniture and fixtures 7 743 647 Leasehold improvements 2 1,191 1,151 Total property and equipment $ 50,038 $ 42,073 Less accumulated depreciation and amortization (35,551) (27,862) Property and equipment—net $ 14,487 $ 14,211 Depreciation expense related to property and equipment amounted to $8,753, $7,552, and $6,832 for the fiscal years ended January 31, 2020, 2019, and 2018, respectively. Assets under capital leases included in computer equipment were $12,283 and $10,235 at January 31, 2020 and 2019, respectively. Accumulated amortization of assets under capital lease was $7,724 and $5,369 at January 31, 2020 and 2019, respectively. (c) Capitalized internal-use software For the fiscal years ended January 31, 2020 and 2019, the Company capitalized $5,852 and $5,109 of costs related to the Phreesia Platform, respectively. During the fiscal years ended January 31, 2020, 2019, and 2018 amortization expense of capitalized internal-use software was $4,933, $4,009, and $2,808, respectively. As of January 31, 2020 and January 31, 2019, the net book value of the Phreesia Platform was $8,735 and $7,816, respectively. (d) Intangible assets and goodwill The following presents the details of intangible assets as of January 31, 2020 and January 31, 2019. January 31, 2020 Gross carrying amount Accumulated amortization Net Life Remaining useful life (in years) Acquired technology $ 490 $ (112) $ 378 5 3.9 Customer Relationship 980 (159) 821 7 5.9 $ 1,470 $ (271) $ 1,199 January 31, 2019 Gross carrying amount Accumulated amortization Net Life Remaining useful life (in years) Acquired technology $ 490 $ (14) $ 476 5 4.8 Customer Relationship 980 (19) 961 7 6.8 $ 1,470 $ (33) $ 1,437 Amortization expense associated with intangible assets for the fiscal years ended January 31, 2020 and 2019 was $238 and $33. There was no amortization expense in fiscal 2018. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2020: Year Ending January 31, 2021 $ 238 2022 238 2023 238 2024 224 Thereafter 261 $ 1,199 The carrying amount of goodwill as of January 31, 2020 and 2019 was $250 related to the Vital Score Acquisition. There were no acquisitions or divestitures in the year ended January 31, 2020. (e) Deferred offering costs Deferred offering costs consist primarily of accounting, legal, and other fees related to the Company's IPO. Prior to the IPO, all deferred offering costs were capitalized in other assets on the accompanying balance sheet. As of January 31, 2020, a total of $6,412 in deferred offering costs related to the IPO was recorded in stockholders' deficit as a reduction of additional paid in capital. Deferred offering costs of $540 were recorded within other assets on the accompanying balance sheet as of January 31, 2019. (f) Accounts receivable Accounts Receivable at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Billed $ 22,245 $ 15,954 Unbilled 676 636 22,921 16,590 Less: Allowance for doubtful accounts (943) (517) $ 21,978 $ 16,073 (g) Prepaid and other current assets Prepaid and other current assets at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Prepaid software and business systems $ 1,611 $ 1,804 Prepaid insurance 1,259 88 Prepaid data center expenses 751 920 Prepaid PhreesiaPads 645 435 Other prepaid expenses and other current assets 891 564 $ 5,157 $ 3,811

Revenue recognition

Revenue recognition	12 Months Ended
	Jan. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue recognition	Revenue recognition The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s provider customers for access to the Phreesia Platform, payment processing fees based on patient payment volume processed through the Phreesia Platform, and from digital patient engagement revenue from life sciences companies to reach, educate and communicate with patients when they are most receptive and actively seeking care. The Company has adopted Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, using the full retrospective method which applied ASC 606 to all periods presented. The Company accounts for revenue from contracts with customers by applying the requirements of Topic 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions and other factors, including other groupings such as customer type. Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare provider organizations that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads) and on-site kiosks (Arrivals Stations) and any other applications. The Company’s provider clients are typically billed monthly in arrears, though in some instances provider clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for provider subscriptions is recognized over the term of the respective provider contract. Services revenues are recognized over the respective non-cancelable subscription term because of the continuous transfer of control to the customer. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Stations through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 840, Leases . The amount of subscription and related services revenues recorded pursuant to ASC 840 for the leasing of the Company’s self-service intake tablets and onsite kiosks was $5,985, $4,749, and $3,544 for the fiscal years ended January 31, 2020, 2019, and 2018, respectively. In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Stations), on-site support and training. The majority of the Company’s professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients. Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two business days after the transaction occurs. At the end of each month, the Company bills its customers for any payment processing fees owed per its customer contractual agreements. Similarly, at the end of each month, the Company remits payments to third-party payment processors and financial institutions for interchange and assessment fees, processing fees, and bank settlement fees. The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. Life sciences The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to targeted patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by revenue source on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees and digital marketing solutions sold to life sciences companies. In addition, all of the Company’s revenue is derived from customers in the United States. Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either: contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). Contract balances Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from its subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheet. Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. The following table represents a rollforward of contract assets and contract liabilities: Contract assets (unbilled accounts receivable) Contract liabilities (deferred revenue) February 1, 2018 $ 107 $ 4,886 Contract asset additions 615 — Amount transferred to receivables from contract assets (86) — Increases due to invoicing prior to satisfaction of performance obligations — 5,900 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (4,298) January 31, 2019 $ 636 $ 6,488 Contract asset additions 671 — Amount transferred to receivables from contract assets (631) — Increases due to invoicing prior to satisfaction of performance obligations — 11,650 Revenue recognized in the period — (7,485) Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (5,252) January 31, 2020 $ 676 $ 5,401 Cost to obtain a contract The Company capitalizes sales commissions paid to internal sales personnel that are incremental to the acquisition of customer contracts. These costs are recorded as deferred contract acquisition costs on the accompanying balance sheets. The Company determines whether costs should be deferred based on its sales compensation plans and if the commissions are incremental and would not have occurred absent the customer contract. Sales commission for subscription and related services are recorded when earned by our sales team. The majority of our sales commissions are considered to be costs of obtaining our customer contracts and as a result are capitalized and then amortized over a period of benefit that the Company has estimated to be three years. The Company determined the period of benefit by taking into consideration its customer contracts, its technology and other factors. Amortization is recognized on a straight-line basis commensurate with the pattern of revenue recognition. Amortization expense is included in sales and marketing expenses in the accompanying statements of operations and totaled $1,977, $1,640, and $1,389 for the fiscal years ended January 31, 2020, 2019, and 2018, respectively. The Company periodically reviews these deferred contract acquisition costs to determine whether events or changes in circumstances have occurred that could impact the period of benefit. There were no impairment losses recorded during the periods presented. The following table represents a rollforward of deferred contract acquisition costs: January 31, 2020 2019 Beginning balance $ 3,194 $ 2,334 Additions to deferred contract acquisition costs 2,097 2,500 Amortization of deferred contract acquisition costs (1,977) (1,640) Ending balance 3,314 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,720 1,673 Deferred contract acquisition costs, non current 1,594 1,521 Total deferred contract acquisition costs $ 3,314 $ 3,194

Debt

Debt	12 Months Ended
	Jan. 31, 2020
Debt Disclosure [Abstract]
Debt	Debt As of January 31, 2020 and 2019, the Company had the following outstanding loan balances: January 31, 2020 2019 Term loan $ 20,000 $ 1,042 Line of credit — 7,800 Loan payable — 20,000 Total debt 20,000 28,842 Less current maturities — (97) Less deferred financing costs (937) (996) Plus accrued Final payment 381 169 Long-term debt, net of current portion $ 19,444 $ 27,918 The Company had a loan facility with a commercial bank that provided for a term loan with an original principal amount of $3,500 and a $10,000 revolving line of credit, which was later increased to $20,000. The term loan was interest only, at a floating per annum rate equal to the Prime Rate as quoted by Wall Street Journal print edition less three-quarters of one percent (0.75)%, for 12 months from the date of borrowing followed by 36 monthly payments of principal and interest. Prime Rate was 5.50% as of January 31, 2019. In addition to principal and interest payments due under the Loan facility, the Company was required to make a final payment fee to the lender due upon the earlier of prepayment or maturity of the term loan, which was equal to 5% of the principal balance, or $175. The Company accrued the estimated final payment fee using the effective interest rate, with a charge to interest expense of $6 and $28 for fiscal 2020 and fiscal 2019, respectively, over the term loan amortization period. Interest expense related to the term loan was $16 and $121, including amortization of deferred financing costs of $5 and $23, for fiscal 2020 and fiscal 2019, respectively. For the year ended January 31, 2019, the effective interest rate on the term loan was 7.4%. Borrowings under the term loan were repaid in full with the proceeds from the New Loan Agreement that was entered into on February 28, 2019. Borrowings under the revolving line of credit bore interest at the Prime rate plus 1.00% and were limited to the greater of $20,000 or an amount determined pursuant to a borrowing base. The revolving credit facility had a maturity date of November 2019. Borrowings under this facility were collateralized by substantially all of the assets of the Company and the Company was required to comply with certain financial covenants related to this facility. The Company was in compliance with all covenants as of January 31, 2019. Weighted-average borrowings outstanding under the revolving line of credit were $3,379 and $971 during fiscal 2020 and fiscal 2019, respectively. Interest expense under the revolving line of credit was $166 and $364, including amortization of deferred financing costs of $13 and $248, for the years ended January 31, 2020 and January 31, 2019, respectively. Borrowings under this facility were repaid in full with proceeds from the New Loan Agreement that was entered into on February 28, 2019. On November 7, 2016, the Company entered into a 5-year term loan agreement with two third-party lenders in an aggregate original principal amount of $10,000 plus an additional $10,000 that was available through May 31, 2017 (the Loans Payable). The initial advance of $10,000 was drawn down simultaneously with the execution of the agreement and the second advance of $10,000 was drawn down in May 2017. Borrowings under the Loans Payable were subordinated to borrowings under the term loan and revolving line of credit. The outstanding principal amount of the Loans Payable was subject to interest each month at an interest rate equal to 11% per annum with the Principal was due in 30 equal installments beginning in June 2019. Interest expense related to the Loans Payable was $168 and $2,729, including amortization of deferred financing costs of $0 and $499, for the years ended January 31, 2020 and 2019, respectively. For fiscal 2019, the effective interest rate on the Loan Payable was 13.6%. Borrowings under the Loans Payable were repaid in full with proceeds from the New Loan Agreement that was entered into on February 28, 2019. On February 28, 2019 (the Effective Date), the Company entered into an Amended and Restated Loan and Security Agreement (the New Loan Agreement) that provides for a $20,000 term loan and a revolving credit facility with up to $25,000 of availability. The proceeds from the New Loan Agreement were used to repay in full the term loan, which had a balance of $1,042 at January 31, 2019, the balance due under the line of credit under the prior facility, which was $7,800 at January 31, 2019, and the $20,000 outstanding under the Loans Payable. The Company is also permitted to borrow an additional $10,000 term loan (the Term Loan B Advance) and, subject to the bank’s approval, another $15,000 (the Term Loan C Advance) prior to February 28, 2020. The term loans under the New Loan Agreement bear interest, which is payable monthly, at a floating rate equal to the bank’s prime rate plus 1.50% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the prime plus 0.75%. Principal payments due under the term loans are due in 36 equal monthly installments beginning in March 2021. In addition to principal and interest payments due under the term loans, the Company is required to make a final payment to the lenders due upon the earlier of prepayment or maturity of the term loan, which is equal to 2.75% of the original principal amount. The Company accrues the estimated final payment using the effective interest method resulting in a charge to interest expense of $273 for the year ended January 31, 2020. In connection with the New Loan Agreement, the Company issued warrants to the lenders to purchase an aggregate of 150,274 shares of common stock at an exercise price of $8.02 per share. The warrants expire in February 2029. The fair value of the warrants of $833 was recorded as a debt discount and is being amortized over the term of the new loan and revolving credit facility. If the Company prepays the term loans prior to their respective scheduled maturities, it will also be required to make prepayment fees to the lenders equal to 3% if prepaid on or before the second anniversary of the Effective Date, 2% if prepaid after the second and on or before the third anniversary of funding or 1% if prepaid after the third anniversary of funding of the principal amounts borrowed. Interest expense related to the term loan under the New Loan Agreement was $1,245, including amortization fees of $117, for the year ended January 31, 2020. For the year ended January 31, 2020, the effective interest rate on the term loan was 6.8%. The Company accounted for the settlement of the Loans Payable and the term loan as a debt extinguishment and recorded an expense of $1,073, which is included in other income (expense), and is comprised of the write-off of $773 of deferred financing costs related to these facilities and a $300 prepayment fee related to the Loans Payable. The modification of the revolving line of credit was accounted for as an insubstantial modification. The Company incurred fees of $112 related to the extinguishment and modification. Borrowings under the revolving credit facility are subject to a borrowing base equal to 80% of eligible accounts receivable plus a percentage of recurring revenue, as defined, not to exceed $25,000 in the aggregate. Based on the borrowing base formula under the new facility, the Company has $25,000 of availability at January 31, 2020. Borrowings under the revolving credit facility bear interest, which is payable monthly, at a floating rate equal to the greater of the bank’s prime rate less 0.50%, or 5.0% until such time that EBITDA reaches a defined level, after which time the interest rate is reduced to the greater of prime less 0.75%, or 4.75%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual fee of $100 per year during the first three years of the facility and then $75 per year in years four and five. Interest expense related to the revolving credit facility under the New Loan Agreement was $374, including amortization of deferred financing fees of $116, for the year ended January 31, 2020. The Company is required to pay a fee of 0.15% per year for any unused availability and a termination fee of 1.50% if the revolving credit agreement is terminated prior to its scheduled maturity. The revolving credit facility is due five years from the Effective Date, which is February 28, 2024. The Company’s obligations under the New Loan Agreement are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The New Loan Agreement includes a financial covenant that requires the Company to achieve specified revenue levels, as defined, through January 31, 2020, after which time revenue levels for covenants purposes will be determined by the bank based on the Company’s forecast, subject to certain minimums. The Company is also required to maintain certain liquidity levels, as defined. The Company was in compliance with all covenants of the New Loan Agreement as of January 31, 2020. The New Loan Agreement contains events of default, including, without limitation, events of default upon: (i) failure to make payment pursuant to the terms of the agreement; (ii) violation of covenants; (iii) material adverse changes to the Company’s business; (iv) attachment or levy on the Company’s assets or judicial restraint on its business; (v) insolvency; (vi) significant judgments, orders or decrees for payments by the Company not covered by insurance; (vii) incorrectness of representations and warranties; (viii) incurrence of subordinated debt; (ix) revocation of governmental approvals necessary for the Company to conduct its business; and (x) failure by the Company to maintain a valid and perfected lien on the collateral securing the borrowing. The Company classified all of its borrowings as of January 31, 2020 as long-term debt based on the refinancing under the New Loan Agreement. As of January 31, 2020, the Company’s long-term debt is payable as follows (based on the terms of the New Loan Agreement): Year Ending January 31, 2021 $ — 2022 6,111 2023 6,667 2024 6,667 2025 555 $ 20,000

Stockholder's Equity

Stockholder's Equity	12 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Stockholder's Equity	Stockholder's Equity (a) Common stock The Company closed an IPO on July 22, 2019 and filed an amended and restated certification of incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. Upon completion of the IPO, the Company issued and sold 7,812,500 shares of common stock at an issuance price of $18.00 per share resulting in net proceeds of $130,781, after deducting underwriting discounts and commissions. In addition, all outstanding shares of Convertible Preferred Stock converted into 25,311,535 shares of common stock and the Company issued 588,763 shares of common stock as a result of the cashless exercise of warrants (See Note 10). An additional 168,862 shares of common stock were issued as a result of the cashless exercise of warrants during the year ended January 31, 2020 (See Note 10). January 31, 2020 2019 Shares Amount Shares Amount Common stock 36,610,763 $ 366 1,994,721 $ 20 (b) Preferred stock As of January 31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance: January 31, 2020 2019 Senior redeemable convertible preferred stock (Senior A) — 6,223,202 Senior redeemable convertible preferred stock (Senior B) — 4,185,616 Junior convertible preferred stock — 14,902,717 Warrants to purchase Senior A redeemable convertible preferred stock — 358,979 Warrants to purchase Junior redeemable convertible preferred stock — 222,819 Warrants to purchase common stock 75,137 256,411 Employee stock options and restricted stock units 6,963,870 5,055,505 Total 7,039,007 31,205,249 The number of outstanding shares and amount of preferred stock as of January 31, 2019 were as follows: January 31, 2019 Shares Amount Senior redeemable convertible preferred stock (Senior A) 13,674,365 $ 79,311 Senior redeemable convertible preferred stock (Senior B) 9,197,142 51,872 Senior Preferred 22,871,507 131,183 Junior convertible preferred stock 32,746,041 32,746 Redeemable preferred stock 42,560,530 42,561 Total 98,178,078 $ 206,490 On October 14, 2014 the Company issued 13,674,365 shares of Senior A Preferred at $2.1939 per share (the Senior A Preferred Original Issue Price) for total proceeds of approximately $30,000 and, prior thereto, effected a recapitalization of the previously outstanding Series A-D redeemable preferred stock by exchanging all then existing shares of Series A-D redeemable preferred stock into 33,344,348 shares of Junior Preferred and 43,214,680 shares of Redeemable Preferred (together with the Junior Preferred and Senior Preferred, the Preferred Stock). Issuance costs totaled $1,803. On October 27, 2017 the Company issued 4,598,571 shares of Senior B Preferred at $3.6968 per share (the Senior B Preferred Original Issue Price) for total proceeds of approximately $17,000. On November 29, 2017, the Company issued an additional 4,598,571 shares of Senior B Preferred at the Senior B Preferred Original Issue Price for additional total proceeds of approximately $17,000. Total issuance costs were $1,541. Upon completion of the IPO on July 22, 2019, all of the Company's then outstanding shares of Senior Preferred and Junior Preferred stock automatically converted into an aggregate of 25,311,535 shares of common stock, using the conversion ratio of 1:0.4551, and all of the Company's then outstanding 42,560,530 shares of redeemable preferred stock were cancelled. As of January 31, 2020, there were no shares of convertible or redeemable preferred stock issued or outstanding. In connection with the IPO, the Company's Amended and Restated Certificate of Incorporation became effective, which authorized 20,000,000 shares of undesignated preferred stock with a value of $0.01 per share. (c) Treasury stock The Company regularly grants non-vested stock options, restricted stock units (RSUs), and performance-based RSUs to its employees pursuant to the terms of its stock option and incentive plans (Note 9). Under the provision of the plans, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting, the Company divides the participant's income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost.

Dividends

Dividends	12 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Dividends	Dividends The Common Stock, Junior Preferred and the Redeemable Preferred do not accrue any dividends. From and after the date of the issuance of a share of Senior A Preferred, dividends accrued at the rate per annum of 8% of the Senior A Preferred Original Issue Price on each such share of Senior A Preferred (the “Accruing Dividends”). From and after the date of the issuance of a share of Senior B Preferred, dividends accrued at the rate per annum of 8% of the Senior B Preferred Original Issue Price on each such share of Senior B Preferred. Accruing Dividends accrued, whether or not declared, compounded annually and were cumulative; provided, however, that the Accruing Dividends were subject to certain adjustments. The Accruing Dividends were payable only upon occurrence of certain events, including a voluntary or involuntary liquidation, dissolution or winding up of the Company, a deemed liquidation event, a redemption of the Senior Preferred or upon a Qualified IPO of the Company. Cumulative undeclared dividends totaled $14,837 at January 31, 2019. Preferred stock dividends of $14,955 were paid in connection with the IPO. Redemption

Equity-based compensation

Equity-based compensation	12 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Equity-based compensation	Equity-based compensation (a) Stock options In 2006, the Board of Directors adopted the Company’s 2006 Stock Option Plan, which provided for the issuance of options to purchase up to 151,548 shares of the Company’s common stock to officers, directors, employees, and consultants. Over the years, the Company has amended the plan to increase the shares available for issuance. On October 14, 2014, the Company increased the number of shares available for issuance under the 2006 plan to 4,424,986. The 2006 Stock Option Plan expired on August 2017. In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan (as amended), which currently provides for the issuance of additional options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company's 2019 Stock Option and Incentive Plan (the 2019 Plan), which replaced the 2018 Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee to make equity-based incentive awards to the Company's officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan is 2,139,683 share of common stock. The initial number of shares reserved and available for issuance will automatically increase on February 1, 2020 and each February thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). Options granted under the plans have a maximum term of ten four Effective July 2019, all available shares from expired, terminated, or forfeited awards that remained under the 2006 or 2018 prior stock compensation plans will be available for grant under the 2019 Plan. In June 2019, the Board of Directors also adopted the Company's 2019 Employee Stock Purchase Plan (The ESPP), which became effective immediately prior to the effectiveness of the registration of the Company's initial public offering. The total shares of common stock initially reserved under the ESPP is limited to 855,873 shares. The fair value of stock options is estimated on the date of the grant using the Black-Scholes option pricing model for each of the stock option awards granted. The assumptions are provided below. Expected volatility was based on the stock volatility for comparable publicly traded companies. The Company uses the simplified method as described in SEC Staff Accounting Bulletin (SAB) 107 to estimate the expected life of stock options. Forfeitures are recorded when they occur. The risk-free rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. January 31, 2020 2019 Risk-free interest rate 2.18 % 2.81 % Expected dividends none none Expected term (in years) 6.25 6.25 Volatility 45.15 % 40.00 % Weighted average fair value of grants $ 4.99 $ 3.47 Stock option activity for fiscal 2020 and fiscal 2019 are as follows: Number of options Weighted- average exercise price Weighted- average remaining contractual life (in years) Aggregate Outstanding—February 1, 2018 5,291,791 $ 2.30 Granted during the year 262,566 $ 4.71 Exercised (316,063) $ 1.15 Forfeited and expired (182,789) $ 3.72 Outstanding—January 31, 2019 5,055,505 $ 2.45 Exercisable—January 31, 2019 3,658,339 $ 1.76 Amount vested in fiscal 2019 736,028 $ 3.27 Outstanding—February 1, 2019 5,055,505 $ 2.45 Granted during the year 1,230,382 $ 8.78 Exercised (691,371) $ 2.62 Forfeited (78,064) $ 5.20 Outstanding and expected to vest—January 31, 2020 5,516,452 $ 3.80 6.22 $ 150,152 Exercisable—January 31, 2020 3,824,259 $ 2.41 5.16 $ 109,351 Amount vested in fiscal 2020 978,170 $ 5.31 As of January 31, 2020, there are 2,129,560 shares available for future grant pursuant to the plan to the newly adopted 2019 Plan as well as an additional 855,873 shares available for grant pursuant to the newly adopted ESPP. The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at year end and the exercise price, multiplied by the related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the fiscal year. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the fiscal years ended 2020, 2019, and 2018 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised) was $13,960, $1,355, and $528, respectively. For the fiscal years ended 2020, 2019, and 2018, the Company recorded stock-based compensation expense related to stock options of $2,780, $1,447, and $805, respectively. As of January 31, 2020, there is $6,113 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 2.78 years. Incremental expense associated with the modification of stock options during the year ended January 31, 2020 was $173. (b) Restricted stock units On March 27, 2019 and June 20, 2019, the Company issued 390,794 and 58,589 stock units, respectively, to employees and directors that vest based on both a time-based condition and a performance-based condition. Pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The performance-based condition was based on the sale of the Company or an IPO, as defined. The restricted stock units expire seven Upon completion of the Company's IPO in July 2019, the Company immediately recognized the fair value of the vested units with the unvested portion recognized over the remaining service period. In addition, in August 2019, the Company approved allowing executive officers the ability to receive all or a portion of the bonus (based on its target bonus opportunity for the last half of the fiscal year) in the form of restricted stock units instead of cash. For such executive officers that elected to receive restricted stock units, such award was granted immediately after such election with a value equal to the portion of the target bonus opportunity that the executive offer elected not to receive in cash, and such award vests based on the achievement of the Company's pre-defined performance targets. Further, such officer may earn up to 200% of the target number of restricted stock units based on actual performance, provided certain stipulations are met. Subsequent to the IPO, the Company issued 972,169 time-based restricted stock units and 72,126 performance-based restricted stock units. Restricted stock unit activity for the year ended January 31, 2020 is as follows: Balance, January 31, 2019 20,164 Granted during the year 1,493,678 Vested (43,011) Forfeited and expired (23,413) Balance, January 31, 2020 1,447,418 For the fiscal year 2020, the Company recognized $3,356 in restricted stock unit compensation expense, with $27,503 remaining of total unrecognized costs related to these awards as of January 31, 2020. The total unrecognized costs are expected to be recognized over a weighted-average term of 3.85 years. During fiscal 2020, the Company recorded stock-based compensation expense of $40 related to restricted stock issued in connection with the Vital Score acquisition (Note 17). As of January 31, 2020, there is $115 of total unrecognized compensation cost related to these awards. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense.

Stock warrants

Stock warrants	12 Months Ended
	Jan. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Stock warrants	Stock warrants As of January 31, 2020 and 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants January 31, Warrants to purchase 2020 2019 Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred — 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 75,137 — $ 8.02 February 28, 2029 Total common stock (equity-classified) 75,137 256,411 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance at February 1, 2017 256,411 1,813,076 Exercised — (40,000) Balance—January 31, 2018 256,411 1,773,076 Forfeited — (136,435) Balance—January 31, 2019 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (913,346) (1,636,641) Balance, January 31, 2020 75,137 — The following table is a reconciliation of the warrant liability measured at fair value: Warrant liability Balance at February 1, 2018 $ 3,440 Change in fair value of stock warrants during year 2,058 Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants during year 3,307 Balance at Conversion of convertible preferred stock warrants (8,805) Balance at January 31, 2020 $ — Upon closing of the IPO in July 2019, the Company's outstanding warrants to purchase shares of preferred stock automatically converted into warrants to purchase an aggregate of 581,798 shares of common stock. Upon the conversion, the Company reclassified the warrants to equity and recorded the then current value of the warrant liability on the date of reclassification to additional paid-in-capital. In addition, in July 2019, the holders of these converted common stock warrants to purchase an aggregate of 428,757 shares of common stock completed the cashless exercises of the warrants, resulting in the issuance of an aggregate of 428,757 shares of common stock, where by 70,485 shares of common stock were withheld by the Company to pay for the exercise price of the warrants. The warrants holders of the remaining converted warrants to purchase 153,041 of common stock completed the cashless exercise of the warrants in January 2020, resulting in an issuance of 115,839 shares of common stock, whereby 37,202 shares of common stock were withheld by the Company to pay for the exercise of the warrants. In July and September 2019, the existing common stock warrant holders completed the cashless exercise of the warrants, resulting in the issuance of 256,411 and 75,137 shares of common stock, respectively, whereby 25,919 and 22,114 shares of common stock, respectively, were withheld by the Company to pay for the exercise price of the warrants, and 230,492 and 53,023 shares of common stock were issued, respectively. As of January 31, 2020, 75,137 of existing common stocks remain outstanding.

Fair value measurements

Fair value measurements	12 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximated fair value due to the short-term nature of these instruments. The Company uses certain derivative financial instruments as part of its risk management strategy to reduce its foreign currency risk. The Company recognizes all derivatives on the balance sheet at fair value based on quotes obtained from financial institutions. The fair value of its foreign currency contracts at January 31, 2020 was an asset of $58, which is included in prepaid and other current assets on the accompanying balance sheet. The fair value of its foreign currency contracts at January 31, 2019 was a liability of $143, which is included in Accounts payable on the accompanying balance sheet. The fair value of the foreign currency contracts are considered Level 2 in the fair value hierarchy in fiscal 2020 and 2019. Warrant Liability—The warrant liability was related to the warrants to purchase shares of preferred stock (See Note 10). Upon the closing of the IPO in July 2019, the warrants to purchase the Company's convertible preferred stock were either converted to warrants to purchase common stock or subject to a cashless exercise into shares of common stock. As a result, the warrant liability was remeasured immediately prior to the closing date of the IPO and reclassified to stockholders' equity (deficit). The Company used the Black-Scholes option-pricing model, which incorporated weighted-average inputs and assumptions, to value the warrant liability as of January 31, 2019 and as of the date of conversion. As of January 31, 2019, the warrant liability was valued at $5,498 as a non-current liability on the balance sheet. The following assumptions were used in valuing the warrant liability: January 31, 2019 Series A Junior Redeemable Estimated fair value of preferred stock $ 4.17 $ 2.38 $ 0.79 Exercise price $ 2.88 $ 0.15 $ 0.11 Remaining term (in years) 8.01 2.25 2.25 Risk-free interest rate 2.4 % 1.8 % 1.8 % Expected volatility 37.8 % 38.8 % 38.8 % Dividend yield 0.0 % 0.0 % 0.0 % The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 % The Company refinanced all of its debt on February 28, 2019 (see Note 6) and believes that the face value of its outstanding debt at January 31, 2020 approximates fair value. The changes in Level 3 warrant liability for the years ended January 31, 2020 and 2019 are reflected in Note 10. The Company did not have any transfers of assets and liabilities between levels of the fair value measurement hierarchy during the years ended January 31, 2020 and 2019.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies (a) Operating and Capital leases The Company leases its office premises in New York, North Carolina and Ottawa under operating leases which expire on various dates through August 2022. The Company recognizes rent expense under such arrangements on a straight-line basis. Rent expense under such operating leases amounted to $1,927, $1,795, and $1,640 for the fiscal years ended January 31, 2020, 2019, and 2018, respectively. As of January 31, 2020, the aggregate minimum net rental payments for non-cancelable operating leases and firmly committed contracts are as follows: January 31, 2021 $ 1,824 2022 819 2023 464 2024 277 $ 3,384 During fiscal year ended January 31, 2020 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 months periods. Minimum lease payments are as follows: January 31, 2021 $ 2,648 2022 1,708 2023 568 $ 4,924 Less: Amounts representing interest (504) $ 4,420 Less: Current portion (2,324) $ 2,096 Interest expense related to capital leases was $580, $290, and $211 for the fiscal years ended January 31, 2020, 2019, and 2018, respectively. (b) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a ny liabilities related to such obligations in our financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require us, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi n g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (c) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows.

Income taxes

Income taxes	12 Months Ended
	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The Company’s loss before income taxes was primarily generated in the United States for fiscal 2020, fiscal 2019 and fiscal 2018. The effective tax rate is 0% for fiscal 2019, and fiscal 2018. The difference between the U.S. statutory rate of 21.0% and the effective tax rate is primarily due to the change in valuation allowance in both fiscal 2019 and 2018. The Company's income tax (benefit) consisted of the following for fiscal 2020: Year ended January 31, 2020 Current tax Domestic $ — Foreign (1,005) Deferred tax Domestic — Foreign (775) Total income tax expense (benefit) $ (1,780) A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the Company's financial statements is as follows: Year ended January 31, 2020 Federal income tax benefit at statutory rate 21.0 % State and local tax, net of federal benefit 2.8 % Permanent differences (1.5) % Equity compensation 6.8 % Foreign taxes 8.1 % Other (4.3) % Change in valuation allowance (24.8) % Effective income tax rate 8.1 % Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for the Company's financial statements and for income tax purposes. The significant components of the Company's deferred tax assets and liabilities as of January 31, 2020 and 2019 are as follows: January 31, Deferred tax assets (liabilities) 2020 2019 Net operating loss carryforwards $ 33,641 $ 29,068 Stock based compensation 1,340 516 Accruals, reserves, and other expenses 329 388 Reserve for bad debts 251 73 Disallowed interest expense 1,358 415 Depreciation and amortization 106 278 Total deferred tax assets 37,025 30,738 Less valuation allowance (35,369) (29,888) Net deferred tax assets 1,656 850 Depreciation and amortization — — Deferred contract acquisition costs (881) (850) Total deferred tax liabilities (881) (850) Deferred taxes, net $ 775 $ — The Company has accumulated a Federal net operating loss carryforward of approximately $124,512, $100,000 and $93,000 as of January 31, 2020, 2019, and 2018, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2020, the Company's foreign branch had net operating loss carryforwards of approximately $2,924, which may be available to offset future income in Canada and will expire beginning in 2030. Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized. On the basis of this evaluation, as of January 31, 2020 and 2019, the Company recorded a valuation allowance of $35,369 and $29,888, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced. Under the Tax Reform Act of 1986, or the Act, the net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss carryforwards could become subject to an annual limitation as the result of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized on a yearly basis to offset future taxable income. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed multiple financings since its inception which may have resulted in an ownership change as defined by Sections 382 of the Internal Revenue Code, or could result in a change in control in the future. The Company has not done an analysis to determine whether or not ownership changes, as defined by the Act, have occurred since inception. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2016 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2020 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities related to its operations in accordance with ASC 740 and adjusts these liabilities when its judgement changes a s a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2020, the Company had no accrued interest or penalties related to uncertain tax positions. The following is a rollforward of the Company's total gross unrecognized tax benefits: January 31, 2020 2019 Unrecognized income tax benefits, opening balance $ 1,000 $ 900 Increase for income tax positions of prior years — 100 Lapse of statute of limitations (1,000) — Unrecognized income tax benefits, ending balance $ — $ 1,000 On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act significantly revises the existing tax law by, among other things, lowering the U.S. corporate income tax rate from 35% to 21% beginning in 2018. The Company reviewed and incorporated the impact of the Tax Act in its tax calculations and disclosures. The Tax Act did not have a significant impact on the Company’s financial statements for the year ended January 31, 2020.

Net loss per share and unaudite

Net loss per share and unaudited pro forma net loss per share attributable to common stockholders	12 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Net loss per share and unaudited pro forma net loss per share attributable to common stockholders	Net loss per share and unaudited pro forma net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended January 31, 2020 2019 2018 Numerator: Net loss $ (20,293) $ (15,062) (18,192) Preferred stock dividends paid (14,955) — — Accretion of Convertible Preferred to redemption value (56,175) (30,199) (19,981) Net loss attributable to common stockholders $ (91,423) $ (45,261) (38,173) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 20,301,189 1,844,929 1,538,600 Net loss attributable to common stockholders, basic and diluted $ (4.50) $ (24.53) $ (24.81) The Company’s potential dilutive securities, which include Convertible Preferred, stock options and outstanding warrants to purchase shares of common and preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended January 31, 2020 2019 Convertible Preferred (as-converted to common stock) — 25,311,535 Stock options to purchase common stock and restricted stock units 6,963,870 5,055,505 Warrants to purchase Convertible Preferred — 581,798 Warrants to purchase common stock 75,137 256,411 Total 7,039,007 31,205,249

Retirement savings plan

Retirement savings plan	12 Months Ended
	Jan. 31, 2020
Retirement Benefits [Abstract]
Retirement savings plan	Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in years ended January 31, 2020 and 2019.

Related party transactions

Related party transactions	12 Months Ended
	Jan. 31, 2020
Related Party Transactions [Abstract]
Related party transactions	Related party transactionsThe Company recognized revenue totaling approximately $5,318, $5,181, and $4,882 from an affiliate of a stockholder of the Company during the fiscal years ended January 31, 2020, 2019, and 2018, respectively. Accounts receivable from the affiliate totaled approximately $2,072 and $598 as of January 31, 2020 and 2019, respectively.

Acquisition

Acquisition	12 Months Ended
	Jan. 31, 2020
Business Combinations [Abstract]
Acquisition	AcquisitionOn December 4, 2018, the Company entered into an asset purchase agreement with Vital Score, Inc. (Vital Score) to acquire all of the assets, and assumed certain of the liabilities, of Vital Score. The acquisition of Vital Score expanded the Company’s clinical and patient activation offerings and deepened its capabilities in motivational science. The acquisition consideration was comprised of cash consideration consisting of (i) $1,540 with $1,190 payable upon the closing of the acquisition and $350 payable on the first anniversary; and (ii) 40,327 shares of common stock issued to the two principals of Vital Score which vest 50% at closing and 50% in 4 equal annual installments beginning on the one-year anniversary of closing provided that the principals are still employed at the Company. These shares were valued at $8.03 per share. In addition, the principals can receive up to $750 in contingent consideration based upon the achievement of certain sales goals. Since 50% of the shares of common stock and the contingent consideration are contingent upon the principals continued service with the Company, these amounts will be recorded as compensation expense and not included in the purchase price. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration $ 1,540 Common stock issued (20,164 shares at $8.03 per share) 162 Total fair value of acquisition consideration $ 1,702 The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Property and equipment $ 5 Acquired technology 490 Customer relationships 980 Goodwill 250 Total assets acquired $ 1,725 Accounts payable (23) Total purchase price $ 1,702 The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimated fair values. The identifiable intangible assets principally included acquired technology and customer relationships, both of which are subject to amortization on a straight-line basis and are being amortized over 5 and 7 years, respectively. The weighted average amortization period for acquired intangible assets as of the date of acquisition is 5.8 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Vital Score. The fair value of the acquired technology was estimated using the cost to replace method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each client grouping. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is deductible for income tax purposes. The Company believes the goodwill related to the acquisition was a result of providing the Company a complementary service offering that will enable the Company to leverage its services with existing and new clients. The goodwill is deductible for income tax purposes. Revenue from Vital Score is primarily comprised of fees from customers using its Motivational Indexing Product. Revenue for these services and the related costs are recognized each month as performance obligations are satisfied and costs are incurred, and are included in subscription and related services and cost of revenues (excluding depreciation and amortization), respectively, in the statements of operations. For the period from December 4, 2018 (date of acquisition) to January 31, 2019, the results of Vital Score are included in the Company’s results and were immaterial. For the year ended January 31, 2018, the unaudited revenues and unaudited net loss of Vital Score were approximately $250 and $455, respectively. For the period from February 1, 2018 through December 4, 2018, the unaudited revenues and unaudited net loss of Vital Score were approximately $100 and $600, respectively.

Subsequent events

Subsequent events	12 Months Ended
	Jan. 31, 2020
Subsequent Events [Abstract]
Subsequent events	Subsequent Events Due to the government-imposed quarantines and other public health safety measures put into place in March 2020, COVID-19's disruption in our provider client's ability to engage with patients has impacted the Company's subscription and related services, patient processing, and life sciences revenues for the fiscal quarter ended April 30, 2020. Phreesia will continue to assess the impact of the COVID-19 pandemic on the Company. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted. The CARES Act is an emergency economic stimulus package in response to the COVID-19 outbreak, which among other things, provides provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is currently evaluating any other applicable implications of the CARES Act, and its impact on the financial statements and related disclosures has not yet been determined.

Selected Quarterly Financial Da

Selected Quarterly Financial Data	12 Months Ended
	Jan. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data	Selected Quarterly Financial Data (unaudited) The following table sets forth selected unaudited quarterly statements of operations data for each of the eight quarters in fiscal 2020 and 2019 (in thousands, except per share data): Quarter ended 1/31/2020 10/31/2019 7/31/2019 4/30/2019 1/31/2019 10/31/2018 7/31/2018 4/30/2018 Statements of Operations data: Total revenue $ 32,815 $ 32,843 $ 30,816 $ 28,310 $ 26,483 $ 24,756 $ 24,779 $ 23,871 Operating loss (4,672) (2,231) (4,140) (4,255) (3,299) (3,036) (1,249) (1,910) Net loss (3,668) (2,437) (7,493) (6,695) (5,080) (4,172) (2,587) (3,224) Net loss per share, basic and diluted (0.10) (0.07) (1.10) (3.32) (2.58) (2.18) (1.46) (1.86)

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Jan. 31, 2020
Accounting Policies [Abstract]
Basis of presentation	Basis of presentationThe accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) and include the accounts of Phreesia, Inc. and its branch operation in Canada.
Fiscal year	Fiscal yearThe Company’s fiscal year ends on January 31, 2020. References to fiscal 2020, 2019, and 2018 refer to the fiscal year ended January 31, 2020, 2019, and 2018, respectively.
Reclassifications	ReclassificationsA reclassification was made from amounts included in accounts payable to accrued liabilities and from amounts included in accounts receivable to prepaid and other current assets on the balance sheet and statement of cash flows as of January 31, 2019 to conform and be comparable to the presentation on the balance sheet and statement of cash flows as of January 31, 2020. A reclassification was also made to reflect the deferred contract acquisition costs as an adjustment to net loss on the statement of cash flows as of January 31, 2019 and January 31, 2018 to conform and be comparable to the presentation on the statement of cash flows as of January 31, 2020. In the prior periods, the deferred contract acquisition costs were netted against the change in the assets. The reclassifications had no effect on net earnings or cash flows as previously reported.
Use of estimates	Use of estimatesThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of stock warrants, the fair value of its business acquisitions, and the realization of deferred tax assets.
Revenue recognition	Revenue recognitionThe Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information about the adoption of ASC 606, Revenue from Contracts with Customers, as well as for additional details about the Company's products and service lines.
Cost of revenue (excluding depreciation and amortization)	Cost of revenue (excluding depreciation and amortization)Cost of revenue (excluding depreciation and amortization) primarily consists of costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Platform such as hosting fees, certain fees paid to various third party partners for the use of their technology, and personnel expenses for implementation and technical support. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
Payment processing expense	Payment processing expensePayment processing expense consists primarily of interchange fees set by payment card networks and that are ultimately paid to the card-issuing financial institution, assessment fees paid to payment card networks, and fees paid to third-party payment processors and gateways.
Sales and marketing	Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $251, $134, and $17 for the fiscal years ended 2020, 2019, and 2018, respectively.
Research and development	Research and developmentResearch and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
General and administrative	General and administrativeGeneral and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and amortization	DepreciationDepreciation represents depreciation expense for PhreesiaPads and Arrivals Stations (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.AmortizationAmortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
Cash and cash equivalents	Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents.
Settlement assets	Settlement assetsSettlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two
Settlement obligations	Settlement obligationsSettlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts receivable	Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time accounts are past due, a customer’s current ability to pay its obligations to the Company, and the condition of the industry as a whole. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2020 and 2019, the Company has reserved $943 and $517 for the allowance for doubtful accounts. Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5).
Property and equipment	Property and equipment Property and equipment, including PhreesiaPads, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three seven Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
Capitalized internal-use software	Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC Topic 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets. The Company exercises judgment in determining the point at which various projects may be capitalized, in assessing the ongoing value of the capitalized costs and in determining the estimated useful lives over which the costs are amortized. To the extent that the Company changes the manner in which it develops and tests new features and functionalities related to its solutions, assesses the ongoing value of capitalized assets or determines the estimated useful lives over which the costs are amortized, the amount of internal-use software development costs the Company capitalizes and amortizes could change in future periods. Refer to Note 4(c) for further detail on internal-use software costs capitalized during the period.
Business combinations	Business combinationsThe Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the statement of operations.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, it is necessary to perform the two-step goodwill impairment test. The two-step goodwill impairment test begins with a comparison of the estimated fair value of the reporting unit to the carrying value of the reporting unit. The first step, commonly referred to as a “step-one impairment test,” is a screen for potential impairment while the second step measures the amount of impairment if there is an indication from the first step that one exists. All other intangible assets associated with purchased intangibles, consisting of customer relationships and acquired technology are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets	Long-lived assetsLong-lived assets, such as property and equipment and intangible assets, including capitalized internal-use software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Income taxes	Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, disclosure, and transition. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision (benefit) from income taxes.
Segment information	Segment informationOperating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Since we operate in one operating segment, all required financial segment information can be found in the financial statements.
Redeemable preferred stock	Redeemable preferred stockAll of the Company’s redeemable preferred stock was classified outside of stockholders’ deficit because the shares contain certain redemption features that are not solely within the control of the Company. At the time of issuance, the redeemable preferred stock was recorded at its issuance price, less issuance costs. The carrying values of the Senior Preferred were accreted to their redemption values at each reporting period, which was equal to the greater of (i) the original issuance price plus unpaid accrued dividends or (ii) the fair value of the Senior Preferred. The Junior Preferred and Redeemable Preferred were accreted to their redemption amount, which is $1.00 per share. The Company records changes in the redemption value of redeemable preferred stock immediately as they occur as if the end of the reporting period was the redemption date for the instrument. As of the year ended January 31, 2020, all redeemable preferred stock has been converted or cancelled in connection with the IPO on July 22, 2019.
Stock-based compensation	Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units (RSUs), and performance-based RSUs. The compensation for the stock-based awards is recognized in accordance with ASC 718, Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.
Warrant liability	Warrant liabilityWarrants to purchase shares of the Company’s redeemable preferred stock were classified as warrant liability on the fiscal 2019 accompanying balance sheet and recorded at fair value. This warrant liability was subject to re-measurement at each balance sheet date and the Company recognized any change in fair value in its statements of operations as a change in fair value of the warrant liability. The Company adjusted the carrying value of the warrants for changes in the estimated fair value in all periods leading up to the IPO, at which time such warrants converted into warrants to purchase shares of common stock. In connection with the IPO, the liabilities were reclassified to additional paid-in capital, a component of stockholders’ deficit.
Fair value of financial instruments	Fair value of financial instruments Certain assets and liabilities are carried at fair value under generally accepted accounting principles. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Concentrations of credit risk, Risks and uncertainties	Concentrations of credit risk Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of Cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily physician’s offices located in the United States and pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for fiscal 2020 and fiscal 2019. As of January 31, 2020, one customer accounted for 15% of accounts receivable. As of January 31, 2019, the Company did not have any individual customers that represented more than 10% of accounts receivable.
Deferred offering costs	Deferred offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ deficit as a reduction of additional paid-in capital generated as a result of the offering. Should the equity financing no longer be considered
Foreign currency	Foreign currencyThe Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other income (expense).
New accounting pronouncements	New accounting pronouncements JOBS Act accounting election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. The Company has elected to early adopt certain new accounting standards, as disclosed herein. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently adopted accounting pronouncements In March 2016, the FASB issued ASU 2016-9, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting , with guidance regarding the simplification of accounting for share-based payment award transactions. The update changes the accounting for such areas as the accounting and cash flow classification for excess tax benefits and deficiencies; forfeitures; and tax withholding requirements and cash flow classification. This guidance was effective for public companies for annual and interim periods beginning after December 15, 2016, with early adoption permitted. The Company adopted the new guidance effective February 1, 2017, and it did not have a material effect on its financial statements. In May 2017, the FASB issued ASU 2017-9, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting , which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This guidance was effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017, with early adoption permitted. The amendments in this ASU are applied prospectively to an award modified on or after the adoption date. The Company adopted the new guidance effective February 1, 2018, and it did not have a material effect on its financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments , with guidance intended to reduce the diversity in practice regarding how certain cash receipts and cash payments are presented and classified within the statement of cash flows. The update addresses eight specific cash flow issues including: debt prepayment or debt extinguishment costs; the settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies or bank-owned life insurance policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. This guidance was effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted the new guidance effective February 1, 2018, and it did not have a material effect on its financial statements. In June 2018, the FASB issued ASU 2018-7, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which largely aligns the accounting for share-based payment awards issued to nonemployees with the accounting for share-based payment awards issued to employees. Under previous GAAP, the accounting for nonemployee share-based payments differed from that applied to employee awards, particularly with regard to the measurement date and the impact of performance conditions. Under the new guidance, (i) equity-classified share-based payment awards issued to nonemployees will be measured at the grant date, instead of the previous requirement to re-measure the awards through the performance completion date, (ii) for performance conditions, compensation cost associated with the award will be recognized when the achievement of the performance condition is probable, rather than upon achievement of the performance condition, and (iii) the current requirement to reassess the classification (equity or liability) for nonemployee awards upon vesting will be eliminated, except for awards in the form of convertible instruments. This new guidance is effective for public companies for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year and early adoption is permitted. The Company adopted ASU 2018-7 as of February 1, 2018 and the impact was not material. Recent accounting pronouncement not yet adopted In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) : Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13). ASU 2018-13 updates the disclosure requirements for fair value measurements and is effective for financial statements issued for fiscal years beginning after December 15, 2019. The Company is currently evaluating the potential impact of the adoption of this standard on the Company’s financial statements. On February 1, 2020, the Company adopted FASB ASU No. 2016-02, Leases (Topic 842) which requires lessees to record most leases on their balance sheets but to recognize the expenses in their statement of operations in a manner similar to the prior standard. Topic 842 states that a lessee recognizes a lease liability for the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term. The Company adopted the new lease guidance using a modified retrospective transition method applied to those leases which were not completed as of February 1, 2020. As a result, the Company was not required to adjust its comparative period financial information for effects of the standard or make the new required lease disclosures for the periods before the date of adoption. The Company elected the ‘package of practical expedients,’ which permits the Company not to reassess under the new standard our prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight practical expedient. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all of its leases. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, including existing short-term leases as of the transition date. The Company also elected the practical expedient to not separate lease and non-lease components for all leases. Upon adoption of Topic 842 we expect to recognize operating lease right-of-use assets and operating lease liabilities related to our office leases of approximately $2.8 million and $3.0 million, respectively. The Company’s accounting for lessee finance and all lessor leases remains substantially unchanged from legacy guidance. The standard is not expected to have a significant impact on our statements of operations or statements of cash flows. In June 2016, the FASB issued ASU 2016-13, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The update requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument. We adopted the new guidance effective February 1, 2020, and it did not have a material effect on our financial statements.

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	12 Months Ended
	Jan. 31, 2020
Composition of Certain Financial Statement Captions [Abstract]
Schedule of accrued expenses	Accrued expenses at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Payment processing fees liability $ 2,738 $ 2,267 Commission and bonus 3,100 320 Payroll 1,360 267 Accrued payment related to acquisition of Vital Score — 350 Vacation 573 417 Other 1,472 1,886 Total $ 9,243 $ 5,507
Schedule of property and equipment	Property and equipment at January 31, 2020 and 2019 are as follows: Useful life January 31, 2020 2019 PhreesiaPads and Arrivals Stations 3 $ 26,389 $ 22,747 Computer equipment 3 18,394 14,338 Computer software 3 2,297 2,166 Hardware development 3 1,024 1,024 Furniture and fixtures 7 743 647 Leasehold improvements 2 1,191 1,151 Total property and equipment $ 50,038 $ 42,073 Less accumulated depreciation and amortization (35,551) (27,862) Property and equipment—net $ 14,487 $ 14,211
Schedule of intangible assets	The following presents the details of intangible assets as of January 31, 2020 and January 31, 2019. January 31, 2020 Gross carrying amount Accumulated amortization Net Life Remaining useful life (in years) Acquired technology $ 490 $ (112) $ 378 5 3.9 Customer Relationship 980 (159) 821 7 5.9 $ 1,470 $ (271) $ 1,199 January 31, 2019 Gross carrying amount Accumulated amortization Net Life Remaining useful life (in years) Acquired technology $ 490 $ (14) $ 476 5 4.8 Customer Relationship 980 (19) 961 7 6.8 $ 1,470 $ (33) $ 1,437
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2020: Year Ending January 31, 2021 $ 238 2022 238 2023 238 2024 224 Thereafter 261 $ 1,199
Schedule of accounts receivable	Accounts Receivable at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Billed $ 22,245 $ 15,954 Unbilled 676 636 22,921 16,590 Less: Allowance for doubtful accounts (943) (517) $ 21,978 $ 16,073
Schedule of prepaid and other current assets	Prepaid and other current assets at January 31, 2020 and 2019 are as follows: January 31, 2020 2019 Prepaid software and business systems $ 1,611 $ 1,804 Prepaid insurance 1,259 88 Prepaid data center expenses 751 920 Prepaid PhreesiaPads 645 435 Other prepaid expenses and other current assets 891 564 $ 5,157 $ 3,811

Revenue recognition (Tables)

Revenue recognition (Tables)	12 Months Ended
	Jan. 31, 2020
Revenue from Contract with Customer [Abstract]
Rollforward of contract assets and contract liabilities	The following table represents a rollforward of contract assets and contract liabilities: Contract assets (unbilled accounts receivable) Contract liabilities (deferred revenue) February 1, 2018 $ 107 $ 4,886 Contract asset additions 615 — Amount transferred to receivables from contract assets (86) — Increases due to invoicing prior to satisfaction of performance obligations — 5,900 Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (4,298) January 31, 2019 $ 636 $ 6,488 Contract asset additions 671 — Amount transferred to receivables from contract assets (631) — Increases due to invoicing prior to satisfaction of performance obligations — 11,650 Revenue recognized in the period — (7,485) Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period — (5,252) January 31, 2020 $ 676 $ 5,401
Deferred contract acquisition costs	The following table represents a rollforward of deferred contract acquisition costs: January 31, 2020 2019 Beginning balance $ 3,194 $ 2,334 Additions to deferred contract acquisition costs 2,097 2,500 Amortization of deferred contract acquisition costs (1,977) (1,640) Ending balance 3,314 3,194 Deferred contract acquisition costs, current (to be amortized in next 12 months) 1,720 1,673 Deferred contract acquisition costs, non current 1,594 1,521 Total deferred contract acquisition costs $ 3,314 $ 3,194

Debt (Tables)

Debt (Tables)	3 Months Ended	12 Months Ended
	Apr. 30, 2019	Jan. 31, 2020
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of January 31, 2020 and 2019, the Company had the following outstanding loan balances: January 31, 2020 2019 Term loan $ 20,000 $ 1,042 Line of credit — 7,800 Loan payable — 20,000 Total debt 20,000 28,842 Less current maturities — (97) Less deferred financing costs (937) (996) Plus accrued Final payment 381 169 Long-term debt, net of current portion $ 19,444 $ 27,918
Schedule of maturities of long-term debt		As of January 31, 2020, the Company’s long-term debt is payable as follows (based on the terms of the New Loan Agreement): Year Ending January 31, 2021 $ — 2022 6,111 2023 6,667 2024 6,667 2025 555 $ 20,000

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	12 Months Ended
	Jan. 31, 2020
Equity [Abstract]
Schedule of Stock Outstanding and Reserve for Future Issuance	January 31, 2020 2019 Shares Amount Shares Amount Common stock 36,610,763 $ 366 1,994,721 $ 20 As of January 31, 2020 and 2019, the Company has reserved the following shares of common stock for future issuance: January 31, 2020 2019 Senior redeemable convertible preferred stock (Senior A) — 6,223,202 Senior redeemable convertible preferred stock (Senior B) — 4,185,616 Junior convertible preferred stock — 14,902,717 Warrants to purchase Senior A redeemable convertible preferred stock — 358,979 Warrants to purchase Junior redeemable convertible preferred stock — 222,819 Warrants to purchase common stock 75,137 256,411 Employee stock options and restricted stock units 6,963,870 5,055,505 Total 7,039,007 31,205,249
Schedule of preferred stock outstanding shares and amount	The number of outstanding shares and amount of preferred stock as of January 31, 2019 were as follows: January 31, 2019 Shares Amount Senior redeemable convertible preferred stock (Senior A) 13,674,365 $ 79,311 Senior redeemable convertible preferred stock (Senior B) 9,197,142 51,872 Senior Preferred 22,871,507 131,183 Junior convertible preferred stock 32,746,041 32,746 Redeemable preferred stock 42,560,530 42,561 Total 98,178,078 $ 206,490

Equity-based compensation (Tabl

Equity-based compensation (Tables)	12 Months Ended
	Jan. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of weighted average assumptions	The risk-free rate was based on the U.S. Treasury yield curve at the time of the grant over the expected term of the stock option grants. January 31, 2020 2019 Risk-free interest rate 2.18 % 2.81 % Expected dividends none none Expected term (in years) 6.25 6.25 Volatility 45.15 % 40.00 % Weighted average fair value of grants $ 4.99 $ 3.47
Schedule of stock option activity	Stock option activity for fiscal 2020 and fiscal 2019 are as follows: Number of options Weighted- average exercise price Weighted- average remaining contractual life (in years) Aggregate Outstanding—February 1, 2018 5,291,791 $ 2.30 Granted during the year 262,566 $ 4.71 Exercised (316,063) $ 1.15 Forfeited and expired (182,789) $ 3.72 Outstanding—January 31, 2019 5,055,505 $ 2.45 Exercisable—January 31, 2019 3,658,339 $ 1.76 Amount vested in fiscal 2019 736,028 $ 3.27 Outstanding—February 1, 2019 5,055,505 $ 2.45 Granted during the year 1,230,382 $ 8.78 Exercised (691,371) $ 2.62 Forfeited (78,064) $ 5.20 Outstanding and expected to vest—January 31, 2020 5,516,452 $ 3.80 6.22 $ 150,152 Exercisable—January 31, 2020 3,824,259 $ 2.41 5.16 $ 109,351 Amount vested in fiscal 2020 978,170 $ 5.31
Schedule of restricted stock unit activity	Restricted stock unit activity for the year ended January 31, 2020 is as follows: Balance, January 31, 2019 20,164 Granted during the year 1,493,678 Vested (43,011) Forfeited and expired (23,413) Balance, January 31, 2020 1,447,418

Stock warrants (Tables)

Stock warrants (Tables)	12 Months Ended
	Jan. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Stock Warrants	As of January 31, 2020 and 2019, the following warrants to purchase common and preferred stock were outstanding: Number of warrants January 31, Warrants to purchase 2020 2019 Exercise price Expiration Senior A Preferred — 116,232 $ 2.19 October 1, 2021 Senior A Preferred — 672,560 $ 3.00 November 1, 2026 Junior Preferred — 489,605 $ 0.01 September 5, 2020 Redeemable Preferred — 358,244 $ 0.01 September 5, 2020 Total preferred stock (liability-classified) — 1,636,641 Common stock — 166,952 $ 2.02 October 21, 2025 Common stock — 89,459 $ 3.49 November 1, 2026 Common stock 75,137 — $ 8.02 February 28, 2029 Total common stock (equity-classified) 75,137 256,411 The following table summarizes the activity for the Company’s warrants for the periods presented: Common Preferred Balance at February 1, 2017 256,411 1,813,076 Exercised — (40,000) Balance—January 31, 2018 256,411 1,773,076 Forfeited — (136,435) Balance—January 31, 2019 256,411 1,636,641 Granted 150,274 — Conversion of preferred stock warrants to common stock warrants 581,798 — Exercised (913,346) (1,636,641) Balance, January 31, 2020 75,137 — The following table is a reconciliation of the warrant liability measured at fair value: Warrant liability Balance at February 1, 2018 $ 3,440 Change in fair value of stock warrants during year 2,058 Balance at January 31, 2019 $ 5,498 Change in fair value of stock warrants during year 3,307 Balance at Conversion of convertible preferred stock warrants (8,805) Balance at January 31, 2020 $ —

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Jan. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of measure the fair market value of the warrant liability	The following assumptions were used in valuing the warrant liability: January 31, 2019 Series A Junior Redeemable Estimated fair value of preferred stock $ 4.17 $ 2.38 $ 0.79 Exercise price $ 2.88 $ 0.15 $ 0.11 Remaining term (in years) 8.01 2.25 2.25 Risk-free interest rate 2.4 % 1.8 % 1.8 % Expected volatility 37.8 % 38.8 % 38.8 % Dividend yield 0.0 % 0.0 % 0.0 % The Black Scholes Method and following assumptions were used to measure the fair market value of the warrant liability upon the conversion date: Series A Junior Estimated fair value of preferred stock $ 18.00 $ 18.00 Exercise price $ 6.33 $ 0.01 Remaining term (in years) 6.55 1.13 Risk-free interest rate 1.9 % 1.9 % Expected volatility 45.9 % 45.9 % Dividend yield 0.0 % 0.0 %

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Jan. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of aggregate minimum net rental payments	As of January 31, 2020, the aggregate minimum net rental payments for non-cancelable operating leases and firmly committed contracts are as follows: January 31, 2021 $ 1,824 2022 819 2023 464 2024 277 $ 3,384
Schedule of minimum lease payments	During fiscal year ended January 31, 2020 and in prior years, the Company entered into several capital leases for equipment and software. The leases are for 30-36 months periods. Minimum lease payments are as follows: January 31, 2021 $ 2,648 2022 1,708 2023 568 $ 4,924 Less: Amounts representing interest (504) $ 4,420 Less: Current portion (2,324) $ 2,096

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jan. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of income tax (benefit)	The Company's income tax (benefit) consisted of the following for fiscal 2020: Year ended January 31, 2020 Current tax Domestic $ — Foreign (1,005) Deferred tax Domestic — Foreign (775) Total income tax expense (benefit) $ (1,780)
Schedule of effective tax rate	A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the Company's financial statements is as follows: Year ended January 31, 2020 Federal income tax benefit at statutory rate 21.0 % State and local tax, net of federal benefit 2.8 % Permanent differences (1.5) % Equity compensation 6.8 % Foreign taxes 8.1 % Other (4.3) % Change in valuation allowance (24.8) % Effective income tax rate 8.1 %
Schedule of deferred tax assets and liabilities	The significant components of the Company's deferred tax assets and liabilities as of January 31, 2020 and 2019 are as follows: January 31, Deferred tax assets (liabilities) 2020 2019 Net operating loss carryforwards $ 33,641 $ 29,068 Stock based compensation 1,340 516 Accruals, reserves, and other expenses 329 388 Reserve for bad debts 251 73 Disallowed interest expense 1,358 415 Depreciation and amortization 106 278 Total deferred tax assets 37,025 30,738 Less valuation allowance (35,369) (29,888) Net deferred tax assets 1,656 850 Depreciation and amortization — — Deferred contract acquisition costs (881) (850) Total deferred tax liabilities (881) (850) Deferred taxes, net $ 775 $ —
Schedule of unrecognized tax benefits	The following is a rollforward of the Company's total gross unrecognized tax benefits: January 31, 2020 2019 Unrecognized income tax benefits, opening balance $ 1,000 $ 900 Increase for income tax positions of prior years — 100 Lapse of statute of limitations (1,000) — Unrecognized income tax benefits, ending balance $ — $ 1,000

Net loss per share and unaudi_2

Net loss per share and unaudited pro forma net loss per share attributable to common stockholders (Tables)	12 Months Ended
	Jan. 31, 2020
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Year ended January 31, 2020 2019 2018 Numerator: Net loss $ (20,293) $ (15,062) (18,192) Preferred stock dividends paid (14,955) — — Accretion of Convertible Preferred to redemption value (56,175) (30,199) (19,981) Net loss attributable to common stockholders $ (91,423) $ (45,261) (38,173) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 20,301,189 1,844,929 1,538,600 Net loss attributable to common stockholders, basic and diluted $ (4.50) $ (24.53) $ (24.81)
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Year ended January 31, 2020 2019 Convertible Preferred (as-converted to common stock) — 25,311,535 Stock options to purchase common stock and restricted stock units 6,963,870 5,055,505 Warrants to purchase Convertible Preferred — 581,798 Warrants to purchase common stock 75,137 256,411 Total 7,039,007 31,205,249

Acquisition (Tables)

Acquisition (Tables)	3 Months Ended
	Apr. 30, 2019
Business Combinations [Abstract]
Summary of Purchase Price Consideration Based on Estimated Acquisition Fair Value	The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration $ 1,540 Common stock issued (20,164 shares at $8.03 per share) 162 Total fair value of acquisition consideration $ 1,702
Schedule of Final Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition: Property and equipment $ 5 Acquired technology 490 Customer relationships 980 Goodwill 250 Total assets acquired $ 1,725 Accounts payable (23) Total purchase price $ 1,702

Selected Quarterly Financial _2

Selected Quarterly Financial Data (Tables)	12 Months Ended
	Jan. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table sets forth selected unaudited quarterly statements of operations data for each of the eight quarters in fiscal 2020 and 2019 (in thousands, except per share data): Quarter ended 1/31/2020 10/31/2019 7/31/2019 4/30/2019 1/31/2019 10/31/2018 7/31/2018 4/30/2018 Statements of Operations data: Total revenue $ 32,815 $ 32,843 $ 30,816 $ 28,310 $ 26,483 $ 24,756 $ 24,779 $ 23,871 Operating loss (4,672) (2,231) (4,140) (4,255) (3,299) (3,036) (1,249) (1,910) Net loss (3,668) (2,437) (7,493) (6,695) (5,080) (4,172) (2,587) (3,224) Net loss per share, basic and diluted (0.10) (0.07) (1.10) (3.32) (2.58) (2.18) (1.46) (1.86)

Background and liquidity (Detai

Background and liquidity (Detail) $ / shares in Units, $ in Thousands	Dec. 17, 2019USD ($)shares	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 03, 2019	Jan. 31, 2020USD ($)shares	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)
Subsidiary, Sale of Stock [Line Items]
Reverse stock split, ratio			2.1973
Proceeds from IPO				$ 130,781	$ 0	$ 0
Payment of offering costs				6,217	195	0
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares		25,311,535
Dividend paid				$ 14,955	$ 0	$ 0
Common stock
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in initial public offering, net of issuance costs (in shares) | shares	7,762,500			7,812,500
Payment of offering costs	$ 1,047
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares		25,311,535		25,311,535
IPO
Subsidiary, Sale of Stock [Line Items]
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares) | shares		588,763
Dividend paid		$ 14,955
IPO | Common stock
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in initial public offering, net of issuance costs (in shares) | shares		7,812,500
Issue price per share (in usd per share) | $ / shares		$ 18
Proceeds from IPO		$ 130,781
Underwriting discounts and commission		9,844
Payment of offering costs		$ 6,412
IPO | Common stock | Certain Selling Stockholders
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock in initial public offering, net of issuance costs (in shares) | shares		2,868,923

Summary of significant accoun_3

Summary of significant accounting policies (Detail)	3 Months Ended	12 Months Ended
	Apr. 30, 2019	Jan. 31, 2020USD ($)segmentprocessors$ / shares	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)	Feb. 01, 2020USD ($)
Accounting Policies [Line Items]
Advertising expense		$ 251,000	$ 134,000	$ 17,000
Allowance for doubtful accounts		943,000	517,000
Asset impairment charges		$ 0	$ 0	$ 0
Number of operating segment | segment		1
Number of reporting units | segment		1
Number of reportable segments | segment		1
Redeemable preferred stock, redemption price per share (in dollars per share) | $ / shares		$ 1
Number of 3rd party payment processors | processors		1
Customer Concentration Risk | Accounts Receivable | Largest Customer
Accounting Policies [Line Items]
Accounts receivable concentration percentage		15.00%
Subsequent Event | Topic 842
Accounting Policies [Line Items]
Operating lease right of use asset					$ 2,800,000
Operating lease liability					$ 3,000,000
Internal-use software
Accounting Policies [Line Items]
Useful life	3 years
Minimum
Accounting Policies [Line Items]
Settlement period		1 day
Useful life (years)		3 years
Payment terms		30 days
Maximum
Accounting Policies [Line Items]
Settlement period		2 days
Useful life (years)		7 years
Payment terms		60 days

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of accrued expenses (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Composition of Certain Financial Statement Captions [Abstract]
Payment processing fees liability	$ 2,738	$ 2,267
Commission and bonus	3,100	320
Payroll	1,360	267
Accrued payment related to acquisition of Vital Score	0	350
Vacation	573	417
Other	1,472	1,886
Total	$ 9,243	$ 5,507

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of property and equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 50,038	$ 42,073
Less accumulated depreciation and amortization	(35,551)	(27,862)
Property and equipment—net	$ 14,487	14,211
PhreesiaPads and Arrivals Stations
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Total property and equipment	$ 26,389	22,747
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Total property and equipment	$ 18,394	14,338
Computer software
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Total property and equipment	$ 2,297	2,166
Hardware development
Property, Plant and Equipment [Line Items]
Useful life (years)	3 years
Total property and equipment	$ 1,024	1,024
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life (years)	7 years
Total property and equipment	$ 743	647
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life (years)	2 years
Total property and equipment	$ 1,191	$ 1,151

Composition of certain financ_5

Composition of certain financial statement captions - Additional Information (Detail) - USD ($)	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018	Jul. 22, 2019
Composition of Certain Financial Statement Captions [Abstract]
Depreciation	$ 8,753,000	$ 7,552,000	$ 6,832,000
Capital leased assets, gross	12,283,000	10,235,000
Accumulated amortization of capital lease assets	7,724,000	5,369,000
Capitalized cost of computer software	5,852,000	5,109,000
Capitalized computed software amortization	4,933,000	4,009,000	2,808,000
Capitalized computer software net	8,735,000	7,816,000
Amortization expense	238,000	33,000	$ 0
Goodwill	250,000	250,000
Deferred offering costs		$ 540,000		$ 6,412,000
Additional deferred offering costs	$ 6,412,000

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of intangible assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,470	$ 1,470
Accumulated amortization	(271)	(33)
Intangible assets, net	1,199	1,437
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	490	490
Accumulated amortization	(112)	(14)
Intangible assets, net	$ 378	$ 476
Life	5 years	5 years
Remaining useful life (in years)	3 years 10 months 24 days	4 years 9 months 18 days
Customer Relationship
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 980	$ 980
Accumulated amortization	(159)	(19)
Intangible assets, net	$ 821	$ 961
Life	7 years	7 years
Remaining useful life (in years)	5 years 10 months 24 days	6 years 9 months 18 days

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of future amortization expense (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Composition of Certain Financial Statement Captions [Abstract]
Year Ending January 31, 2021	$ 238
Year Ending January 31, 2022	238
Year Ending January 31, 2023	238
Year Ending January 31, 2024	224
Thereafter	261
Intangible assets, net	$ 1,199	$ 1,437

Composition of certain financ_8

Composition of certain financial statement captions - Schedule of accounts receivable (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 22,921	$ 16,590
Less: Allowance for doubtful accounts	(943)	(517)
Total accounts receivable	21,978	16,073
Billed
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	22,245	15,954
Unbilled
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 676	$ 636

Composition of certain financ_9

Composition of certain financial statement captions - Schedule of prepaid and other current assets (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Composition of Certain Financial Statement Captions [Abstract]
Prepaid software and business systems	$ 1,611	$ 1,804
Prepaid insurance	1,259	88
Prepaid data center expenses	751	920
Other prepaid expenses and other current assets	891	564
Prepaid PhreesiaPads	645	435
Prepaid expenses and other current assets	$ 5,157	$ 3,811

Revenue recognition - Additiona

Revenue recognition - Additional Information (Detail) - USD ($)	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Disaggregation of Revenue [Line Items]
Capitalized contract cost, amortization period	3 years
Deferred contract acquisition cost amortization	$ 1,977,000	$ 1,640,000	$ 1,389,000
Capitalized contract cost, impairment loss	0	0	0
Subscription and related services
Disaggregation of Revenue [Line Items]
Revenues recorded pursuant to ASC 840	$ 5,985,000	$ 4,749,000	$ 3,544,000

Revenue recognition - Rollforwa

Revenue recognition - Rollforward of contract assets and contract liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Contract assets (unbilled accounts receivable)
Beginning balance	$ 636	$ 107
Contract asset additions	671	615
Amount transferred to receivables from contract assets	(631)	(86)
Ending balance	676	636
Contract liabilities (deferred revenue)
Beginning balance	6,488	4,886
Increases due to invoicing prior to satisfaction of performance obligations	11,650	5,900
Revenue recognized in the period	(7,485)
Performance obligations satisfied during the period that were included in the contract liability balance at the beginning of the period	(5,252)	(4,298)
Ending balance	$ 5,401	$ 6,488

Revenue recognition - Schedule

Revenue recognition - Schedule of Deferred contract acquisition costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2020	Jan. 31, 2019
Capitalized Contract Cost [Roll Forward]
Beginning balance	$ 3,194	$ 2,334
Additions to deferred contract acquisition costs	2,097	2,500
Amortization of deferred contract acquisition costs	(1,977)	(1,640)	$ (1,389)
Ending balance	3,314	3,194	2,334
Deferred contract acquisition costs, current (to be amortized in next 12 months)				$ 1,720	$ 1,673
Deferred contract acquisition costs, non current				1,594	1,521
Total deferred contract acquisition costs	$ 3,194	$ 3,194	$ 2,334	$ 3,314	$ 3,194

Debt - Schedule Of Outstanding

Debt - Schedule Of Outstanding loan balances (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Debt Instrument [Line Items]
Line of credit	$ 20,000	$ 28,842
Less current maturities	0	(97)
Less deferred financing costs	(937)	(996)
Plus accrued Final payment	381	169
Long-term debt, net of current portion	19,444	27,918
Term loan
Debt Instrument [Line Items]
Line of credit	20,000	1,042
Plus accrued Final payment	6	28
Line of credit
Debt Instrument [Line Items]
Line of credit	0	7,800
Loan payable
Debt Instrument [Line Items]
Line of credit	$ 0	$ 20,000

Debt - Additional Information (

Debt - Additional Information (Detail)	Feb. 28, 2019USD ($)$ / sharesshares	Nov. 07, 2016USD ($)installment	May 31, 2017USD ($)	Jan. 31, 2020USD ($)	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)
Debt Instrument [Line Items]
Plus accrued Final payment				$ 381,000	$ 169,000
Long term debt gross				20,000,000	28,842,000
Amortization of debt discount				445,000	798,000	$ 904,000
Loss on extinguishment of debt				1,073,000	0	$ 0
Amended And Restated Loan And Security Agreement
Debt Instrument [Line Items]
Interest expense				$ 1,245,000
Effective interest rate percentage				6.80%
Estimated final payment charged to interest expense				$ 273,000
Number of warrants (in shares) | shares	150,274
Exercise price (in dollars per share) | $ / shares	$ 8,020
Common stock warrants outstanding	$ 833,000
Prepayment fee percentage after first anniversary	3.00%
Prepayment fee percentage after second anniversary	2.00%
Prepayment fee percentage after third anniversary	1.00%
Amortization of debt discount				$ 117,000
Amended And Restated Loan And Security Agreement | Prime Rate | Before EBITDA Benchmark
Debt Instrument [Line Items]
Variable rate	1.50%
Amended And Restated Loan And Security Agreement | Prime Rate | After EBITDA Benchmark
Debt Instrument [Line Items]
Variable rate	0.75%
Term loan
Debt Instrument [Line Items]
Borrowing capacity					3,500,000
Expiration period				36 months
Debt instrument fee percentage				5.00%
Prepayment fee				$ 175,000
Plus accrued Final payment				6,000	28,000
Interest expense				16,000	121,000
Amortization of financing costs				5,000	23,000
Effective interest rate percentage						7.40%
Long term debt gross				$ 20,000,000	1,042,000
Term loan | Prime Rate
Debt Instrument [Line Items]
Variable rate				(0.75%)
Term loan | Amended And Restated Loan And Security Agreement
Debt Instrument [Line Items]
Borrowing capacity	$ 20,000,000
Debt instrument fee percentage	2.75%
Long term debt gross					1,042,000
Loan payable
Debt Instrument [Line Items]
Expiration period		5 years
Interest expense				$ 168,000	2,729,000
Amortization of financing costs				0	$ 499,000
Effective interest rate percentage					13.60%
Debt, additional available amount		$ 10,000,000
Proceeds from lines of credit		$ 10,000,000	$ 10,000,000
Stated interest percentage		11.00%
Number of installment payments | installment		30
Long term debt gross				0	$ 20,000,000
Loss on extinguishment of debt				1,073,000
Write-off of deferred financing costs				773,000
Debt prepayment fee				300,000
Debt extinguishment and modification fee				112,000
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity				20,000,000	10,000,000
Interest expense				166,000	364,000
Amortization of financing costs				13,000	248,000
Debt, borrowing capacity				20,000,000
Weighted-average borrowings outstanding				$ 3,379,000	971,000
Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Variable rate				1.00%
Revolving Credit Facility | Prime Rate | Before EBITDA Benchmark
Debt Instrument [Line Items]
Variable rate				(0.50%)
Revolving Credit Facility | Prime Rate | After EBITDA Benchmark
Debt Instrument [Line Items]
Variable rate				(0.75%)
Revolving Credit Facility | Amended And Restated Loan And Security Agreement
Debt Instrument [Line Items]
Borrowing capacity				$ 25,000,000
Expiration period				5 years
Debt instrument fee percentage				0.15%
Interest expense				$ 374,000
Debt, borrowing capacity				25,000,000
Long term debt gross					$ 7,800,000
Amortization of debt discount				$ 116,000
Borrowing base as a percentage of accounts receivable				80.00%
Annual fee per year during the first three years				$ 100,000
Annual fee per year in years four and five				$ 75,000
Termination fee percentage				1.50%
Revolving Credit Facility | Amended And Restated Loan And Security Agreement | Before EBITDA Benchmark
Debt Instrument [Line Items]
Stated interest percentage				5.00%
Revolving Credit Facility | Amended And Restated Loan And Security Agreement | After EBITDA Benchmark
Debt Instrument [Line Items]
Stated interest percentage				4.75%
Term Loan B Advance
Debt Instrument [Line Items]
Expiration period	36 months
Term Loan B Advance | Amended And Restated Loan And Security Agreement
Debt Instrument [Line Items]
Borrowing capacity	$ 10,000,000
Term Loan C Advance
Debt Instrument [Line Items]
Expiration period	36 months
Term Loan C Advance | Amended And Restated Loan And Security Agreement
Debt Instrument [Line Items]
Borrowing capacity	$ 15,000,000

Debt - Schedule of long-term de

Debt - Schedule of long-term debt maturities (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Debt Disclosure [Abstract]
2021	$ 0
2022	6,111
2023	6,667
2024	6,667
2025	555
Long-term debt, gross	$ 20,000	$ 28,842

Stockholder's Equity - Common S

Stockholder's Equity - Common Stock, Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 17, 2019	Jul. 22, 2019	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Class of Stock [Line Items]
Common stock authorized (in shares)		500,000,000	500,000,000	80,000,000
Common stock, par value (in usd per share)		$ 0.01	$ 0.01	$ 0.01
Proceeds from IPO			$ 130,781	$ 0	$ 0
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535
Cashless exercise of common stock warrants (in shares)		588,763	168,862
Common stock
Class of Stock [Line Items]
Stock issued during period (in shares)	7,762,500		7,812,500
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535	25,311,535
Cashless exercise of common stock warrants (in shares)			168,862
IPO
Class of Stock [Line Items]
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		588,763
IPO | Common stock
Class of Stock [Line Items]
Stock issued during period (in shares)		7,812,500
Share price (in usd per share)		$ 18
Proceeds from IPO		$ 130,781

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of common stock is entitled to one vote per share (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Equity [Abstract]
Shares (in shares)	36,610,763	1,994,721
Amount	$ 366	$ 20

Stockholder's Equity - Schedu_2

Stockholder's Equity - Schedule of Shares Reserved For Future Issuance (Detail) - shares	Jan. 31, 2020	Jan. 31, 2019
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	7,039,007	31,205,249
Employee stock options and restricted stock units
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	6,963,870	5,055,505
Warrants to purchase Senior A redeemable convertible preferred stock
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	0	358,979
Warrants to purchase Junior redeemable convertible preferred stock
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	0	222,819
Warrants to purchase common stock
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	75,137	256,411
Senior redeemable convertible preferred stock (Senior A)
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	0	6,223,202
Senior redeemable convertible preferred stock (Senior B)
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	0	4,185,616
Junior convertible preferred stock
Class of Stock [Line Items]
Common stock shares reserved for future issuance (in shares)	0	14,902,717

Stockholder's Equity - Schedu_3

Stockholder's Equity - Schedule of preferred stock outstanding shares and amount (Details) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)		98,178,078
Redeemable preferred stock	$ 0	$ 206,490	$ 176,291	$ 123,823
Senior Preferred
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)		22,871,507
Redeemable preferred stock		$ 131,183
Senior redeemable convertible preferred stock (Senior A)
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)		13,674,365	13,674,365	13,674,365
Redeemable preferred stock	$ 0	$ 79,311	$ 57,022	$ 48,544
Senior redeemable convertible preferred stock (Senior B)
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)	0	9,197,142	9,197,142	0
Redeemable preferred stock	$ 0	$ 51,872	$ 43,962	$ 0
Junior convertible preferred stock
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)	0	32,746,041	32,746,041	32,718,098
Redeemable preferred stock	$ 0	$ 32,746	$ 32,746	$ 32,718
Redeemable preferred stock
Temporary Equity [Line Items]
Temporary equity, shares outstanding (in shares)	0	42,560,530	42,560,530	42,560,530
Redeemable preferred stock	$ 0	$ 42,561	$ 42,561	$ 42,561

Stockholder's Equity - Preferre

Stockholder's Equity - Preferred Stock, Additional Information (Details) $ / shares in Units, $ in Thousands	Dec. 17, 2019USD ($)	Jul. 22, 2019USD ($)$ / sharesshares	Jul. 03, 2019	Nov. 29, 2017USD ($)shares	Oct. 27, 2017USD ($)$ / sharesshares	Oct. 14, 2014USD ($)$ / sharesshares	Jan. 31, 2020USD ($)shares	Jan. 31, 2019USD ($)shares	Jan. 31, 2018USD ($)
Temporary Equity [Line Items]
Proceeds from issuance of preferred shares | $							$ 0	$ 0	$ 32,459
Issuance costs incurred | $							$ 6,217	$ 195	0
Conversion ratio			2.1973
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535
Preferred stock authorized (in shares)		20,000,000
Preferred stock par value (in usd per share) | $ / shares		$ 0.01
IPO
Temporary Equity [Line Items]
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		588,763
Common stock
Temporary Equity [Line Items]
Issuance costs incurred | $	$ 1,047
Conversion of preferred stock into common stock and cancellation of redeemable preferred stock (in shares)		25,311,535					25,311,535
Common stock | IPO
Temporary Equity [Line Items]
Issuance costs incurred | $		$ 6,412
Senior redeemable convertible preferred stock (Senior A)
Temporary Equity [Line Items]
Redeemable preferred stock, shares issued (in shares)						13,674,365		13,674,365
Price per share of stock issued (in usd per share) | $ / shares						$ 2.1939
Proceeds from issuance of preferred shares | $						$ 30,000
Issuance costs incurred | $						$ 1,803
Junior Preferred Stock
Temporary Equity [Line Items]
Preferred stock issued in exchange (in shares)						33,344,348
Redeemable preferred stock
Temporary Equity [Line Items]
Redeemable preferred stock, shares issued (in shares)								42,560,530
Preferred stock issued in exchange (in shares)						43,214,680
Preferred stock, shares cancelled (in shares)		42,560,530
Senior redeemable convertible preferred stock (Senior B)
Temporary Equity [Line Items]
Redeemable preferred stock, shares issued (in shares)				4,598,571	4,598,571			9,197,142
Price per share of stock issued (in usd per share) | $ / shares					$ 3.6968
Proceeds from issuance of preferred shares | $				$ 17,000	$ 17,000
Issuance costs incurred | $				$ 1,541					$ 1,541

Dividends (Detail)

Dividends (Detail) - USD ($) $ in Thousands	Jul. 22, 2019	Jan. 31, 2020	Jan. 31, 2019
Dividends Payable [Line Items]
Preferred stock dividends paid		$ 14,955
IPO
Dividends Payable [Line Items]
Preferred stock dividends paid	$ 14,955
Senior redeemable convertible preferred stock (Senior A)
Dividends Payable [Line Items]
Dividend rate			8.00%
Senior redeemable convertible preferred stock (Senior B)
Dividends Payable [Line Items]
Dividend rate			8.00%
Senior Preferred
Dividends Payable [Line Items]
Cumulative undeclared dividends			$ 14,837

Equity-based compensation - Add

Equity-based compensation - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 20, 2019	Mar. 27, 2019	Jan. 31, 2020	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018	Jun. 30, 2019	Oct. 14, 2014	Dec. 31, 2006
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options issued (in shares)				1,230,382	262,566
Common stock reserve for future issuance (in shares)			7,039,007	7,039,007	31,205,249
Intrinsic value				$ 13,960	$ 1,355	$ 528
Unrecognized compensation cost to stock option			$ 6,113	6,113
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense				$ 2,780	$ 1,447	$ 805
Weighted average term for recognition				2 years 9 months 10 days
Incremental expense associated with the modification of stock options				$ 173
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term				7 years
Share-based compensation expense				$ 3,356
Weighted average term for recognition				3 years 10 months 6 days
RSU's granted (in shares)	58,589	390,794
Maximum percentage of restricted stock that can be earned				200.00%
Unrecognised compensation costs			27,503	$ 27,503
Restricted Stock Units (RSUs) | Vital Score
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense				40
Unrecognised compensation costs			$ 115	$ 115
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option				10.00%
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option				20.00%
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option				30.00%
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option				40.00%
Time Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted (in shares)			972,169
Performance based restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSU's granted (in shares)			72,126
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant (in shares)			855,873	855,873
2006 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)								4,424,986	151,548
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares)						3,048,490
2019 Stock Option And Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares)							2,139,683
Annual increase in number of additional shares authorized				5.00%
Shares available for future grant (in shares)			2,129,560	2,129,560
2019 Stock Option And Incentive Plan | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term				10 years
Vesting term				4 years
Percentage of vest option				25.00%

Equity-based compensation - Wei

Equity-based compensation - Weighted Average Assumptions (Detail) - Stock Options - $ / shares	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.18%	2.81%
Expected dividends	0.00%	0.00%
Expected term (in years)	6 years 3 months	6 years 3 months
Volatility	45.15%	40.00%
Weighted average fair market value of grants (in dollars per share)	$ 4.99	$ 3.47

Equity-based compensation - Sto

Equity-based compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Number of options
Number of options outstanding, beginning (in shares)	5,055,505	5,291,791
Granted (in shares)	1,230,382	262,566
Exercised (in shares)	(691,371)	(316,063)
Forfeited and expired (in shares)	(78,064)	(182,789)
Number of options outstanding, ending (in shares)	5,516,452	5,055,505
Exercisable (in shares)	3,824,259	3,658,339
Amount vested at the beginning of the period (in shares)	978,170	736,028
Weighted- average exercise price
Weighted- average exercise price outstanding, beginning balance (in dollars per share)	$ 2.45	$ 2.30
Granted (in dollars per share)	8.78	4.71
Exercised (in dollars per share)	2.62	1.15
Forfeited and expired (in dollars per share)	5.20	3.72
Weighted- average exercise price outstanding, ending balance (in dollars per share)	3.80	2.45
Exercisable (in dollars per share)	2.41	1.76
Amount vested at the end of the period (in dollars per share)	$ 5.31	$ 3.27
Outstanding and expected to vest- end of the year	6 years 2 months 19 days
Exercisable- end of the year	5 years 1 month 28 days
Aggregate intrinsic value outstanding and expected to vest	$ 150,152
Aggregate intrinsic value exercisable	$ 109,351

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Restricted Stock Units (Detail) - Restricted Stock	12 Months Ended
	Jan. 31, 2020shares
Restricted Stock Unit Activity:
Beginning balance (in shares)	20,164
Granted (in shares)	1,493,678
Vested (in shares)	(43,011)
Forfeited and expired (in shares)	(23,413)
Ending balance (in shares)	1,447,418

Stock warrants - Warrants to pu

Stock warrants - Warrants to purchase common and preferred stock (Detail) - $ / shares	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Common stock
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	75,137	256,411	256,411	256,411
Common stock | Exercise price 2.02, Expiration October 21, 2025
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	166,952
Exercise price (in dollars per share)	$ 2.02
Common stock | Exercise price 3.49, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	89,459
Exercise price (in dollars per share)	$ 3.49
Common stock | Exercise price 8.02, Expiration February 28, 2029
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	75,137	0
Exercise price (in dollars per share)	$ 8,020
Senior A Preferred | Exercise price 2.19, Expiration October 1, 2021
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	116,232
Exercise price (in dollars per share)	$ 2.19
Senior A Preferred | Exercise price 3.00, Expiration November 1, 2026
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	672,560
Exercise price (in dollars per share)	$ 3
Junior Preferred Stock | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	489,605
Exercise price (in dollars per share)	$ 0.01
Redeemable preferred stock | Exercise price 0.01, Expiration September 5, 2020
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	358,244
Exercise price (in dollars per share)	$ 0.01
Preferred stock
Class of Warrant or Right [Line Items]
Number of warrants (in shares)	0	1,636,641

Stock warrants - Activity for t

Stock warrants - Activity for the Company's warrants (Detail) - shares	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Common
Stock Warrants [Roll Forward]
Beginning balance (in shares)	256,411	256,411	256,411
Forfeited (in shares)		0
Granted (in shares)	150,274
Conversion of preferred stock warrants to common stock warrants (in shares)	581,798
Exercised (in shares)	(913,346)		0
Ending balance (in shares)	75,137	256,411	256,411
Preferred
Stock Warrants [Roll Forward]
Beginning balance (in shares)	1,636,641	1,773,076	1,813,076
Forfeited (in shares)		(136,435)
Granted (in shares)	0
Conversion of preferred stock warrants to common stock warrants (in shares)	0
Exercised (in shares)	(1,636,641)		(40,000)
Ending balance (in shares)	0	1,636,641	1,773,076

Stock warrants - Reconciliation

Stock warrants - Reconciliation of warrant liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Warrant Liability [Roll Forward]
Beginning balance	$ 5,498	$ 3,440
Change in fair value of stock warrants during year	3,307	2,058	$ 598
Conversion of convertible preferred stock warrants	(8,805)
Ending balance	$ 0	$ 5,498	$ 3,440

Stock warrants - Additional Inf

Stock warrants - Additional Information (Details) - USD ($)	1 Months Ended
	Jan. 31, 2020	Sep. 30, 2019	Jul. 31, 2019	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2017
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants (in shares)		75,137	256,411
Common stock withheld (in shares)		22,114	25,919
Common stock issued, net of shares withheld (in shares)		53,023	230,492
Common stock
Class of Warrant or Right [Line Items]
Conversion of preferred stock warrants to common stock warrants (in shares)			581,798
Common stock issued upon the exercise of warrants (in shares)	115,839		428,757
Common stock warrants outstanding			$ 153,041
Number of warrants (in shares)	75,137			256,411	256,411	256,411
Warrants
Class of Warrant or Right [Line Items]
Common stock issued upon the exercise of warrants (in shares)			428,757
Common stock withheld (in shares)	37,202		70,485

Fair value measurements - Addit

Fair value measurements - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 0	$ 5,498	$ 3,440
Accounts Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts, liabilities		$ 143
Prepaid and Other Current Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of foreign currency contracts, assets	$ 58

Fair value measurements - Sched

Fair value measurements - Schedule of weighted-average assumptions (Detail)	Jul. 22, 2019$ / sharesdecimal	Jan. 31, 2019decimal$ / shares
Series A Preferred
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining term	6 years 6 months 18 days	8 years 3 days
Series A Preferred | Estimated fair value of preferred stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	18	4.17
Series A Preferred | Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	6.33	2.88
Series A Preferred | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.019	0.024
Series A Preferred | Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.459	0.378
Series A Preferred | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0	0
Junior Preferred Stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining term	1 year 1 month 17 days	2 years 3 months
Junior Preferred Stock | Estimated fair value of preferred stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	18	2.38
Junior Preferred Stock | Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares	0.01	0.15
Junior Preferred Stock | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.019	0.018
Junior Preferred Stock | Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.459	0.388
Junior Preferred Stock | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0	0
Redeemable preferred stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining term		2 years 3 months
Redeemable preferred stock | Estimated fair value of preferred stock
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares		0.79
Redeemable preferred stock | Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input | $ / shares		0.11
Redeemable preferred stock | Risk-free interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.018
Redeemable preferred stock | Expected volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.388
Redeemable preferred stock | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0

Commitments and contingencies -

Commitments and contingencies - Additional information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Commitments And Contingencies [Line Items]
Operating lease rent expense	$ 1,927	$ 1,795	$ 1,640
Capital lease interest expense	$ 580	$ 290	$ 211
Minimum
Commitments And Contingencies [Line Items]
Capital lease term	30 months
Maximum
Commitments And Contingencies [Line Items]
Capital lease term	36 months

Commitments and contingencies_2

Commitments and contingencies - Schedule of aggregate minimum net rental payments (Detail) $ in Thousands	Jan. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
2021	$ 1,824
2022	819
2023	464
2024	277
Total operating lease payments	$ 3,384

Commitments and contingencies_3

Commitments and contingencies - Schedule of minimum lease payments (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2021	$ 2,648
2022	1,708
2023	568
Total capital lease payments	4,924
Less: Amounts representing interest	(504)
Total capital lease payments, net of interest	4,420
Less: Current portion	(2,324)	$ (1,869)
Total capital lease payments, net of interest and current portion	$ 2,096	$ 2,401

Income taxes - Additional Infor

Income taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Operating Loss Carryforwards [Line Items]
Effective tax rate	8.10%	0.00%	0.00%
Accumulated federal net operating loss carryforward	$ 124,512	$ 100,000	$ 93,000
Valuation allowance	(35,369)	$ (29,888)
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Accumulated federal net operating loss carryforward	$ 2,924

Income taxes - Components of ta

Income taxes - Components of tax (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Current tax
Domestic	$ 0
Foreign	(1,005)
Deferred tax
Domestic	0
Deferred Foreign Income Tax Expense (Benefit)	(775)
Total income tax expense (benefit)	$ (1,780)	$ 0	$ 0

Income taxes - Effective tax ra

Income taxes - Effective tax rate reconciliation (Details)	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate	21.00%
State and local tax, net of federal benefit	2.80%
Permanent differences	(1.50%)
Equity compensation	6.80%
Foreign taxes	8.10%
Other	(4.30%)
Change in valuation allowance	(24.80%)
Effective income tax rate	8.10%	0.00%	0.00%

Income taxes - Company's Deferr

Income taxes - Company's Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019
Deferred tax assets
Net operating loss carryforwards	$ 33,641	$ 29,068
Stock based compensation	1,340	516
Accruals, reserves, and other expenses	329	388
Reserve for bad debts	251	73
Disallowed interest expense	1,358	415
Depreciation and amortization	106	278
Total deferred tax assets	37,025	30,738
Less valuation allowance	(35,369)	(29,888)
Net deferred tax assets	1,656	850
Depreciation and amortization	0	0
Deferred contract acquisition costs	(881)	(850)
Total deferred tax liabilities	(881)	(850)
Deferred taxes, net	$ 775	$ 0

Income taxes - Unrecognized tax

Income taxes - Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized income tax benefits, opening balance	$ 1,000	$ 900
Increase for income tax positions of prior years	0	100
Lapse of statute of limitations	(1,000)	0
Unrecognized income tax benefits, ending balance	$ 0	$ 1,000

Net loss per share attributable

Net loss per share attributable to common stockholders - Schedule of computation (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Numerator:
Net loss	$ (3,668)	$ (2,437)	$ (7,493)	$ (6,695)	$ (5,080)	$ (4,172)	$ (2,587)	$ (3,224)	$ (20,293)	$ (15,062)	$ (18,192)
Preferred stock dividends paid									(14,955)	0	0
Accretion of Convertible Preferred to redemption value									(56,175)	(30,199)	(19,981)
Net loss attributable to common stockholders									$ (91,423)	$ (45,261)	$ (38,173)
Denominator:
Weighted-average shares of common stock outstanding, basic and diluted (in shares)									20,301,189	1,844,929	1,538,600
Net loss attributable to common stockholders (in usd per share)	$ (0.10)	$ (0.07)	$ (1.10)	$ (3.32)	$ (2.58)	$ (2.18)	$ (1.46)	$ (1.86)	$ (4.50)	$ (24.53)	$ (24.81)

Net loss per share attributab_2

Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Detail) - shares	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,039,007	31,205,249
Convertible Preferred (as-converted to common stock)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	25,311,535
Employee stock options and restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,963,870	5,055,505
Warrants | Preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	581,798
Warrants | Common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	75,137	256,411

Retirement savings plan (Detail

Retirement savings plan (Detail) - USD ($)	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019
Retirement Benefits [Abstract]
Company contributions	$ 0	$ 0

Related party transactions (Det

Related party transactions (Detail) - Affiliated Entity - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Related Party Transaction [Line Items]
Recognized revenue	$ 5,318	$ 5,181	$ 4,882
Accounts receivable	$ 598	$ 2,072

Acquisition - Additional Inform

Acquisition - Additional Information (Detail)	Dec. 04, 2018USD ($)installment$ / sharesshares	Dec. 04, 2018USD ($)installment$ / shares	Jan. 31, 2020USD ($)	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)
Business Acquisition [Line Items]
Cash consideration			$ 0	$ 1,190,000	$ 0
Vital Score
Business Acquisition [Line Items]
Cash consideration	$ 1,540,000
Common stock issued (in shares) | shares	40,327
Common stock and contingent consideration vesting percentage at closing	50.00%	50.00%
Common stock and contingent consideration vesting percentage after first year	50.00%	50.00%
Number of common stock vesting installments | installment	4	4
Business acquisition shares value (in dollars per share) | $ / shares	$ 8.03	$ 8.03
Contingent consideration, up to	$ 750,000	$ 750,000
Weighted average amortization period	5 years 9 months 18 days
Business acquisition, revenue		100,000			250,000
Business acquisition, net loss		$ (600,000)			$ (455,000)
Vital Score | Minimum
Business Acquisition [Line Items]
Useful life	5 years
Vital Score | Maximum
Business Acquisition [Line Items]
Useful life	7 years
Vital Score | Payable upon the closing of the acquisition
Business Acquisition [Line Items]
Cash consideration	$ 1,190,000
Common stock issued (in shares) | shares	20,164
Business acquisition shares value (in dollars per share) | $ / shares	$ 8.03	$ 8.03
Vital Score | Payable on the first anniversary
Business Acquisition [Line Items]
Cash consideration	$ 350,000

Acquisition - Summary of Initia

Acquisition - Summary of Initial Purchase Price Consideration (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 04, 2018	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Business Acquisition [Line Items]
Cash consideration		$ 0	$ 1,190	$ 0
Vital Score
Business Acquisition [Line Items]
Common stock issued (in shares)	40,327
Business acquisition shares value (in dollars per share)	$ 8.03
Cash consideration	$ 1,540
Common stock issued (20,164 shares at $8.03 per share)	162
Total fair value of acquisition consideration	$ 1,702
Vital Score | Payable upon the closing of the acquisition
Business Acquisition [Line Items]
Common stock issued (in shares)	20,164
Business acquisition shares value (in dollars per share)	$ 8.03
Cash consideration	$ 1,190

Acquisition - Schedule of Final

Acquisition - Schedule of Final Allocation of Purchase Price (Detail) - USD ($) $ in Thousands	Jan. 31, 2020	Jan. 31, 2019	Dec. 04, 2018
Business Acquisition [Line Items]
Goodwill	$ 250	$ 250
Vital Score
Business Acquisition [Line Items]
Property and equipment			$ 5
Goodwill			250
Total assets acquired			1,725
Accounts payable			(23)
Total purchase price			1,702
Vital Score | Acquired technology
Business Acquisition [Line Items]
Intangible assets			490
Vital Score | Customer relationships
Business Acquisition [Line Items]
Intangible assets			$ 980

Selected Quarterly Financial _3

Selected Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jan. 31, 2020	Oct. 31, 2019	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2020	Jan. 31, 2019	Jan. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 32,815	$ 32,843	$ 30,816	$ 28,310	$ 26,483	$ 24,756	$ 24,779	$ 23,871	$ 124,784	$ 99,889	$ 79,834
Operating loss	(4,672)	(2,231)	(4,140)	(4,255)	(3,299)	(3,036)	(1,249)	(1,910)	(15,298)	(9,494)	(14,553)
Net loss	$ (3,668)	$ (2,437)	$ (7,493)	$ (6,695)	$ (5,080)	$ (4,172)	$ (2,587)	$ (3,224)	$ (20,293)	$ (15,062)	$ (18,192)
Net loss attributable to common stockholders (in usd per share)	$ (0.10)	$ (0.07)	$ (1.10)	$ (3.32)	$ (2.58)	$ (2.18)	$ (1.46)	$ (1.86)	$ (4.50)	$ (24.53)	$ (24.81)